Next Steps for Immunotherapy in Glioblastoma

Toni Q. Cao 1,*, Derek A. Wainwright 2,3,4,5,6, Catalina Lee-Chang 2,3, Jason Miska 2,3, Adam M. Sonabend 2,3, Amy B. Heimberger 2,3 and Rimas V. Lukas 1,3

1 Department of Neurology, Northwestern University, Chicago, IL 60611, USA
2 Department of Neurological Surgery, Northwestern University, Chicago, IL 60611, USA
3 Lou & Jean Malnati Brain Tumor Institute, Chicago, IL 60611, USA
4 Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, IL 60611, USA
5 Department of Neuroscience, Northwestern University, Chicago, IL 60611, USA
6 Department of Microbiology-Immunology, Northwestern University, Chicago, IL 60611, USA
* Correspondence: toni.cao1@nm.org

Abstract: Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy.

Keywords: immunotherapy; glioblastoma; immune system

1. Introduction

Glioblastoma is a primary brain tumor for which there is a substantial unmet need with respect to therapeutic options. Contemporary standard treatment for newly diagnosed disease involves maximum feasible surgical resection, radiation therapy, systemic therapy with the DNA-alkylating agent temozolomide, and regional therapy with alternating electrical fields [1]. For progressive disease, optimal management is less clear [2]. Immunotherapeutic approaches, including vaccines, immune checkpoint inhibitors, or cell-based therapies, have proven remarkably successful in a host of non-central nervous system (CNS) malignancies [3]. Unfortunately, such gains in durable survival have yet to be observed across unselcted patient populations with glioblastoma in the phase 3 trials thus far conducted [4–6]. A number of factors, both known and unknown, contribute to the lack of benefit from immunotherapy observed thus far. In this review, we will examine recent clinical investigations that may shed light on these resistance mechanisms. Additionally, we will identify future approaches that may prove of value in utilizing immunotherapies to treat glioblastoma.

2. Established Immunotherapeutic Approaches: Enhancing T-Cell Activities

Glioblastomas have been shown to promote immunosuppression intratumorally as well as systemically [7,8]. Decreased systemic immune activity is associated with tumor
progression and shorter survival times [9–12]. These findings suggest that immunotherapeutic approaches to enhance immune activity and/or minimize immunosuppression may prove beneficial in treating patients with these tumors. Two of the most extensively studied approaches are vaccine therapies and immune checkpoint inhibitors, as detailed below. Chimeric antigen receptor (CAR) T-cell therapy, which involves the administration of genetically modifying cytotoxic T lymphocytes expressing chimeric antigen receptors for tumor antigens, is reviewed separately [13].

2.1. Vaccine Therapies

Vaccine-based immunotherapy is designed to induce a specific immune response against tumor antigens. Vaccines can be categorized into “off-the-shelf” peptide vaccines targeting pre-specified epitopes or vaccines based on autologous patient tumor tissue [14]. Summaries of both completed and ongoing peptide and autologous vaccine therapies are listed in Table 1.

Table 1. Completed and ongoing peptide vaccine clinical trials for GBM.

| Vaccine Type/Target | Study Title | N (Size) | Intervention Details | Primary Endpoint | Reference |
|---------------------|-------------|----------|----------------------|------------------|-----------|
| EGFRvIII            | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV) | 3 (745) | Rindopepimut + TMZ vs. TMZ | OS = 20.1 (95% CI 18.5–22.1) vs. 20.0 mo (95% CI 18.1–21.9) | NCT01480479 |
|                     | A Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII Positive Glioblastoma (ReACT) | 2 (73) | Rindopepimut + bevacizumab vs. Bevacizumab | PFS at 6 mo = 28% vs. 16% (HR = 0.72, 95% CI 0.42–1.21) | NCT01498328 |
|                     | Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme | 2 (21) | WT1 peptide | mPFS = 20 weeks 6 mo PFS rate = 33.3% | N/A |
| WT1                 | A phase I study of the WT2275 dosing emulsion in patients with advanced malignancies | 1 (62) | WT1 peptide (WT2275) | Maximum tolerated dose. | NCT01621542 |
|                     | IMT-03 Clinical Trial for Newly Diagnosed Malignant Glioma with WT1-W10 Vaccination | 1/2 (27) | WT peptide (W10) | PFS = 12.7 mo OS = 21.9 mo | N/A |
| IDH1                | Targeting IDH1R132H in WHO Grade III-IV IDH1R132H-mutated Gliomas by a Peptide Vaccine—a Phase I Safety, Tolerability and Immunogenicity Multicenter Trial (NOA16) | 1 (33) | IDH1 peptide vaccine | Safety and immunogenicity. 93.3% with vaccine-induced immune response | NCT02454634 |
|                     | Vaccine Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme (ATTAC) | 1/2 (12) | pp65-DC vaccine + Td pre-conditioning | Safety and feasibility * OS = 20.6–47.3 mo vs. 13.8–41.3 mo (p = 0.013) | NCT00639639 |
| CMV                 | Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination (ATTAC-GM) | 1 (11) | pp65 DC vaccine + GM-CSF | Safety and feasibility * mPFS = 25.3 mo vs. 8 mo (p = 0.0001), * mOS = 41.1 vs. 19.2 mo (p = 0.0001) | NCT00639639 |
|                     | Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines with Adjuvant TETanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma (ELEVATE) | 2 (43) | pp65 DC vaccine + TMZ vs. PP65 DC vaccine + TMZ pre-conditioning | 3-year OS = 34% (95% CI 19–63%) vs. 6% (95% CI 1–42%) | NCT02366728 |
| Multipeptide Vaccines | Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma | 1/2 (9) | TAS0313 | Safety and efficacy. ORR = 11.1% (95% CI 0.3–48.2%) | JapicCTI-183824 |
|                     | A Randomized, Double-blind, Controlled Phase Ib Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients with Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation | 2 (124) | ICT-107 vs. placebo | OS = 17 vs. 15 mo (HR = 0.87, p = 0.58), * PFS = 11.2 vs. 9.0 mo (HR = 0.57, p = 0.011) | NCT01280552 |
| Neoantigens         | A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma Patients | 1/1b (8) | NeoVax + RT vs. NeoVax + RT + Pembrolizumab | Safety and tolerability | NCT02267428 |
Table 1. Cont.

| Vaccine Type/Target | Study Title | Phase | Size | Intervention details | Primary endpoint | Reference |
|---------------------|-------------|-------|------|----------------------|------------------|-----------|
| Survivin            | A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma | 2     | 66   | SurVaxM + TMZ         | PFS at 6 mo      | NCT02455557 |
|                     | Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence | 2     | 40   | SurVaxM + pembrolizumab | PFS at 6 mo      | NCT04013672 |
| TERT                | Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma (UCPVax-Glio) | 1/2   | 56   | UCPVax vs. UCPVax + TMZ | Anti-TERT T-cell response | NCT04280848 |
| Multi peptide       | First-in-Human, Phase 1b/2a Trial of a Multi peptide Therapeutic Vaccine in Patients with Progressive Glioblastoma (ROSA1IE) | 1/2   | 52   | EO2041 + nivolumab vs. EO2041 + nivolumab + bevacizumab | Safety and tolerability | NCT04116658 |

EGFRvIII = epidermal growth factor receptor variant III; GM-CSF = granulocyte-macrophage colony-stimulating factor; TMZ = temozolomide; RT = radiotherapy; WT1 = Wilms tumor 1; IDH1 = isocitrate dehydrogenase 1; CMV = cytomegalovirus; Td = tetanus toxoid; DC = dendritic cell; TERT = telomerase reverse transcriptase; OS = overall survival; mOS = median overall survival; PFS = progression-free survival; mPFS = median progression-free survival; HR = hazard ratio; CI = confidence interval; ORR = overall response rate.

* Secondary endpoints.

2.1.1. Peptide Vaccines

**EGFRvIII**: The epidermal growth factor receptor (EGFR) deletion mutation, EGFRvIII, is expressed in about ~33% of GBM and promotes tumorigenesis through various mechanisms [15–23]. Signaling pathways induced by EGFRvIII activation are illustrated in Figure 1. The most notable peptide vaccine is rindopepimut, previously known as CDX-110, which targets EGFRvIII. This vaccine was studied in several clinical trials [24–26]. In the phase 3 ACT IV trial (NCT01480479), the addition of rindopepimut to standard radiation and temozolomide treatment in EGFRvIII-positive glioblastoma patients did not improve survival as compared to radiation and temozolomide alone (20.1 months vs. 20 months, HR 1.01) [27]. Furthermore, there was no significant difference in progression-free survival, tumor response, or quality of life measures in the rindopepimut group compared to the control group [27]. Interestingly, the randomized phase 2 ReACT trial (NCT01498328) demonstrated that the addition of rindopepimut to standard bevacizumab in relapsed, EGFRvIII-positive glioblastoma patients trended toward improved progression-free survival (PFS) at 6 months. While multiple endpoints were positive (overall survival (OS), overall response rate, and median duration of response), the study was overall limited by a small sample size (n = 73 patients) [6].

![Figure 1. EGFRvIII signaling pathways.](image-url)
It should be noted that almost 60% of the patients in the ACT IV trial who were treated with rindopepimut and studied at tumor recurrence (21 of 37 patients evaluated of the 745 patients enrolled) subsequently lost EGFRvIII expression [27]. Loss of EGFRvIII has been described in additional studies [25,26,28]. However, EGFRvIII loss is not limited to those treated with rindopepimut and can still occur in nearly 50% of patients with EGFRvIII expressing glioblastoma as part of the natural evolution of glioblastoma [29].

EGFRvIII (epidermal growth factor receptor variant III) activates multiple signaling pathways for tumorigenesis, including MAPK, mTOR, and STAT pathways.

**IDH1**: Isocitrate dehydrogenase (IDH) 1 mutations are a defining characteristic of the histologically similar tumor, the astrocytoma IDH mutated WHO grade 4, which was previously characterized as a glioblastoma [30,31]. These tumors were previously included in many trials for glioblastoma. Recent attempts have been made to create a peptide vaccine targeting the IDH1 R132H neoantigen. One recent phase 1 clinical trial studied the efficacy of the IDH1 R132H mutant peptide vaccine (NOA-16) in IDH1 mutated grade III–IV gliomas, which led to both mutation-specific T cell and humoral immune responses [32] (NCT02454634).

**WT1**: A number of other antigen peptide-based vaccines are also being explored in GBM. Wilms tumor 1 (WT1) was previously identified as a tumor-associated antigen (TAA) in high-grade glioblastoma [33]. Subsequent clinical trials were performed in humans, demonstrating the safety and tolerability of the WT1 peptide vaccine [34]. The resulting data demonstrated the induction of WT1-specific IgG antibodies as well as the identification of a potential biomarker [35,36]. This is still an actively researched approach [37,38].

**CMV**: Efforts in developing a cytomegalovirus (CMV) peptide vaccine began after one study found CMV immune reactivity in 100% of GBM patients, albeit with some inconsistent results [39–42]. The vaccine is aimed at pp6537, which is a major structural protein of CMV. Two strategies for targeting CMV have been evaluated in GBM: a pp65-pulsed dendritic cell (DC) platform [43] and a CMV-specific T-cell expansion approach [44,45]. These approaches have been shown to be safe, and early small studies have revealed promising results. Two recent sequential clinical trials (ATTAC and its expanded cohort trial ATTAC-GM, NCT00639639) using CMV pp65 DC vaccines in newly diagnosed GBM patients consistently demonstrated an improved OS, with the latter trial demonstrating mPFS of 25.3 mo and OS of 41.1 mo [45,46]. A third larger confirmatory trial, ELEVATE (NCT02366728), involving 43 patients who received the CMV DC vaccine after pretreatment with tetanus diptheria toxoid (Td), demonstrated a 3-year OS of 34% [46,47]. Though these results are encouraging, larger confirmatory studies are needed.

**Survivin**: Survivin is part of the inhibitor of apoptosis (IAP) family of proteins and functions to regulate cell division and programmed cell death [48]. There have also been ongoing efforts using a survivin peptide mimic (SurVaxM) in GBM [49]. This vaccine is currently being evaluated in one phase 2 trial for newly diagnosed GBM (NCT02455557). It is also being studied in combination with pembrolizumab in recurrent GBM in a separate trial (NCT04013672) [50,51]. While the vaccine is well tolerated, efficacy is unknown.

**TERT**: TERT (telomerase reverse transcriptase) mutations occur in many GBM patients [52,53]. As a result, a recent vaccine strategy was developed to target the telomerase reverse transcriptase (TERT) protein [53]. The TERT peptide-based vaccine (UCPVax-Glio) was recently developed by Invectys in France and is currently being studied in both phase 1 and 2 trials (NCT04280848).

**Multipeptide vaccines**: Considering the very real possibility of antigen escape using a single peptide targeting vaccine, the latest class of peptide vaccines were engineered toward multiple tumor antigens simultaneously. An ongoing phase 1/2 study found TAS0313, a vaccine comprised of 12 Cytotoxic T-cell epitopes against 8 TAAs (derived from EGFR, KUA, LCK, MRP3, PTHR1, SART2, SART3, and WHSC2), to be safe and potentially efficacious [54]. In another recent phase 2 study, administration of the ICT-107 vaccine, comprised of 6 TAA (MAGE-1, HER-2, AIM-2, TRP-2, gp100, and IL13Rα2) pulsed into DC, led to a notable increase in PFS in GBM patients [55]. A third vaccine called EO2401, which targets three
bacterial peptides that mimic tumor antigens (termed Oncomimics), is being explored in the context of nivolumab for progressive GBM (NCT04116658) [56]. Interim results are expected soon. While no conventional peptide vaccine platform has led to any change in the standard of care (SOC) of GBM, the results of these studies are eagerly anticipated.

Neoantigens: Cancer neoantigens are T-cell epitopes that exclusively arise from tumor-specific somatic DNA mutations and are subsequently highly immunogenic given the lack of expression in normal tissues [57]. Neoantigen vaccines have been studied previously in patients with melanoma [58–60] but have only recently been studied in the GBM population. A recent phase 1/1b trial (NCT02287428) demonstrated that administration of a personalized neoantigen vaccine (NeoVax) in new GBM patients induced circulating neoantigen-specific T-cell responses and resulted in intratumoral T-cell infiltration, a subset of which were neoantigen-specific [61]. Of note, T-cell response was limited to patients who did not receive concomitant steroid treatment with dexamethasone. Additionally, despite one patient having a large number of unique CD4+ and CD8+ T-cell clonotypes, the actual number of clonotypes identical to those from the relapsed tumor was significantly lower [61].

2.1.2. Autologous Vaccines

A summary of clinical trials investigating autologous vaccines for glioblastoma is listed in Table 2. There have been several studies evaluating autologous vaccines in the context of dendritic cells (DCs) [62,63]. DCs are key players in immunosurveillance and immune regulation that present phagocytosed antigens to naïve T cells. DCVax-L is the most well-studied DC vaccine and is comprised of autologous DCs pulsed with autologous tumor lysate. The phase 3 DCVax trial (NCT00045968) investigated the impact of DCVax-L in addition to SOC (surgical resection and chemoradiotherapy) for newly diagnosed GBM patients. Due to the cross-over study design, nearly 90% of the patients in this study received DCVax-L, making an interpretation of the survival outcome challenging. In the overall intent to treat the patient population (investigational arm + control arm), the mOS was estimated to be 23.1 months. This study has benchmarked these findings to historical controls but has not yet evaluated its primary endpoint of PFS [62]. A recent phase 1 trial focused on an autologous DC vaccine pulsed with GBM stem-like cell line lysate, which was shown to be tolerable (NCT02010606). Further results are pending [63].

Table 2. Autologous vaccine clinical trials for GBM.

| Autologous Vaccine | Study Title                                                                 | Phase | Size  | Intervention                                                                 | Primary Endpoint                                                                 | Reference                  |
|--------------------|-----------------------------------------------------------------------------|-------|-------|------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------|
| Dendritic cells    | A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) | 3     | 331   | TMZ + DCVax-L vs. TMZ + placebo                                              | mOS = 23.1 mo (95% CI 21.2–25.4)                                               | NCT00045968              |
|                    | Phase I Study of a Dendritic Cell Vaccine for Patients with Either Newly Diagnosed or Recurrent Glioblastoma | 1     | 36    | DC vaccine + GBM stem-like cell lysate                                       | Safety and tolerability * mPFS = 8.75 mo in new GBM, 3.23 mo in recurrent GBM * mOS = 20.36 mo in new GBM, 11.97 mo in recurrent GBM | NCT02010606              |
| HSP                | Phase I/II Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Patients With Recurrent High Grade Glioma | 1/2   | 41    | HSPPC-96 vaccine                                                            | OS at 6 mo = 90.2% (95% CI 75.9–96.8%) mOS = 42.6 weeks (95% CI = 34.7–50.5) | NCT00293423              |
|                    | A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma | 2     | 90    | HSPPC-96 vaccine + bevacizumab vs. bevacizumab alone                         | OS = 7.5 vs. 10.7 mo (HR = 2.06)                                                | NCT01814813              |

TMZ = temozolomide; DC = dendritic cell; GBM = glioblastoma multiforme; HSP = heat shock protein; mOS = median overall survival; mPFS = median progression-free survival; CI = confidence interval. * Secondary endpoints.
Heat shock protein (HSP) vaccines are designed to promote a specific antitumor inflammatory response [64]. HSPs operate as intracellular chaperones and can deliver tumor antigens to antigen-presenting cells (APCs), including DCs, to facilitate T cell-mediated cytotoxic death [64]. The most well-studied HSP vaccine is the autologous HSPPC-96 (Prophage) vaccine, which is comprised of patient-specific tumor antigens conjugated to HSP gp-96. A single-arm, phase 2 trial enrolled 41 recurrent GBM patients treated with the HSPPC-96 vaccine (NCT00293423). Results revealed an mOS of 42.6 weeks and mPFS of 19.1 weeks [65]. Notably, these outcomes were only compared to historical controls. A subsequent multi-arm phase 2 clinical trial investigated both HSPPC-96 and bevacizumab, though it was then closed to accrual early after interim analysis demonstrated no improvement in OS [66].

Of note, several of these clinical trials utilized historical controls as the active comparator. Many have deemed the use of historical controls as suboptimal due to potential differences in patient, disease, and therapeutic characteristics that subsequently confound results. Furthermore, historical controls face different survival trends when matched to contemporary patients, likely as a result of evolving therapeutic options [67–69]. Moving forward, the reliability of historical controls should continue to be kept in mind when designing clinical trials.

Other personalized vaccines, such as CeGaT, are commercially available. To the authors’ knowledge, there have been no peer-reviewed preclinical or clinical studies of CeGaT for glioblastoma.

2.2. PD-1 and PD-L1 Blockade

Immune checkpoints regulate the immune system as “gatekeepers” of immune responses to maintain self-tolerance [70]. These immune checkpoints can be stimulated and utilized by tumors, including glioblastomas, to evade the immune system. One of the most well-studied immune checkpoints and therapeutic targets is the PD-1/PD-L1 axis. Glioblastoma tumor cells express programmed death ligand 1 (PD-L1), which binds to PD-1 on T cells (see Figure 2). This induces T-cell apoptosis or anergy and allows tumor cells to evade the immune response [70,71]. Higher expression of PD-L1 is associated with a higher grade and worse outcome [70]. Immune checkpoint inhibitors that block the interaction of PD-1 with PD-L1 can potentially reinstate a T-cell antitumor immune response [71,72]. Here we review major trials studying PD-1 and PD-L1 inhibitors in glioblastoma (Table 3).

![Figure 2. PD-1 and PD-L1 expression. PD-1 (programmed death-1) and PD-L1 (programmed death ligand 1) are expressed in T cell and cancer cells, respectively. Examples of PD-1 blockers include nivolumab, pembrolizumab, and cemiplimab. Examples of PD-L1 blockers include atezolizumab, durvalumab, and avelumab.](image-url)
Table 3. Immune checkpoint inhibitor clinical trials for GBM.

| Study Title                                                                 | Phase | Size | Intervention Details          | Primary Endpoint                  | Reference   |
|----------------------------------------------------------------------------|-------|------|------------------------------|----------------------------------|-------------|
| An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (Checkmate 498) | 3     | 560  | Nivolumab + RT vs. TMZ + RT   | OS (endpoint not met) mOS = 13.4 vs. 14.9 mo (HR = 1.31, 95% CI = 1.09–1.58, p = 0.0037) | NCT02617589 |
| An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (Checkmate 548) | 3     | 716  | Nivolumab + RT + TMZ vs. Placebo + RT + TMZ | PFS = 10.6 vs. 10.3 mo (HR = 1.06) mOS = 28.9 vs. 32.1 mo (HR = 1.10) | NCT02667587 |
| Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (aPDL1) in Combination With Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma (GBM) | 1/2   | 60   | Atezolizumab + RT + TMZ vs. adjuvant atezolizumab + TMZ | MTD, mOS = 17.1 mo | NCT03174197 |
| A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (Checkmate 143) | 3     | 369  | Nivolumab vs. Bevacizumab     | mOS = 9.8 vs. 10.0 mo (HR = 1.04, 95% CI = 0.83–1.30) | NCT02017717 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | 1     | 26   | Pembrolizumab                | mOS = 13.1 mo                    | NCT02054806 |
| Pembrolizumab +/- Bevacizumab for Recurrent GBM                            | 2     | 80   | Pembrolizumab + bevacizum vs. Pembrolizumab | PFS at 6 mo = 26.0% (95% CI 16.3–41.5) vs. 6.7% (95% CI 1.7–25.4) | NCT02337491 |
| A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors | 1     | 16   | Atezolizumab                 | Safety profile, mOS = 4.2 mo     | NCT01375842 |

GBM = glioblastoma multiforme; RT = radiation therapy; TMZ = temozolomide; PDL1 = programmed death ligand 1; OS = overall survival; mOS = median overall survival; PFS = progression-free survival; HR = hazard ratio; CI = confidence interval.

Nivolumab is a human immunoglobulin G4 monoclonal antibody that targets PD-1. After it was approved for several solid tumors, it was studied in several trials for patients with GBM. The phase 3 trial CheckMate 143 demonstrated no improvement in mOS for recurrent GBM patients treated with nivolumab vs. bevacizumab (9.8 vs. 10.0 months, HR 1.04, p = 0.76) [73]. Subsequently, two large phase 3 trials investigated the role of nivolumab in newly diagnosed GBM. In the CheckMate 548 trial, the addition of nivolumab to radiotherapy and temozolomide did not improve OS (mOS 28.9 vs. 32.1 months in nivolumab vs. placebo group, respectively, HR 1.10) or PFS (10.6 months vs. 10.3 months, HR 1.1) in newly diagnosed GBM patients with methylated/indeterminate MGMT promoter [4]. The companion phase 3 CheckMate 498 trial was designed to compare OS for new unmethylated MGMT glioblastoma patients treated with either nivolumab + RT vs. temozolomide + RT. Notably, this trial also did not meet its primary endpoint of prolonged survival (mOS = 13.4 months vs. 14.9 months, HR 1.31, p = 0.0037), and results favored the control arm [5]. The use of dual checkpoint blockade, PD-1, and CTLA-4, is currently undergoing investigation in the NRG Oncology cooperative group in a randomized phase 2/3 trial BN007 (NCT04396860), which has completed the phase 2 accrual. Intracerebral administration of CTLA-4 and PD-1 inhibitors ipilimumab and nivolumab, respectively, in addition to intravenous nivolumab, has also been shown to be safe in a phase 1 trial, with further results pending [74]. One can question from a mechanistic perspective, however, the need for direct intracranial administration.

Pembrolizumab, another anti-PD-1 antibody, has been extensively studied in glioblastoma patients but has also shown to be ineffective at improving mOS. In the KEYNOTE-028 study, results from the phase 1 trial in recurrent PD-L1 positive glioblastoma patients revealed a response rate of 8%. Interpretation of the results is limited due to the small sample
Pembrolizumab was then studied in conjunction with bevacizumab, with the rationale being the latter drug’s possible role in promoting immunotherapy by inhibiting VEGF [76–79]. In this phase 2 trial, patients were randomized to receive either pembrolizumab + bevacizumab vs. pembrolizumab monotherapy to assess PFS at 6 months. Pembrolizumab failed to improve both PFS and OS [80].

Investigations focused on PD-L1 targeting in glioma have been more limited in scope. Atezolizumab, an anti-PD-L1 antibody, was studied in a phase 1 trial. The overall response was 6%, with some long-term survivors [81]. The N2M2/NOA-20 phase 1/2 trial includes an arm investigating atezolizumab in conjunction with asinerecept (APG101), a CD95-Fc fusion protein intended to block apoptosis of activated T cells [82]. Preliminary results of another atezolizumab trial (NCT03174197) suggest that survival outcomes may be associated with differences in the microbiomes of patients [83]. These results have been presented only in abstract form thus far.

These results with checkpoint blockade are not terribly surprising given a number of considerations. First and foremost, glioblastoma patients are lymphopenic, with the T cells sequestered in the bone marrow [8]. Even upon gaining access to the glioblastoma tumor microenvironment (TME), the T cells are exhausted and are unlikely to be reinvigorated with immune checkpoint blockade or other types of immune suppression modulation [84,85]. This is coupled with the immunosuppressive “cold” tumor microenvironment as detailed in the following few sections, overall resulting in low immunogenicity. Additionally, PD-L1 is not frequently expressed in glioblastoma, and even those that do express PD-L1 do not necessarily fare better. In fact, PD-L1 expression was shown to be correlated with an increased risk of death [86]. Furthermore, there are many other redundant mechanisms of immune suppression that do not involve the PD-1/PD-L1 axis, rendering checkpoint inhibitors targeting this specific axis ineffective [85–87]. Lastly, limited drug availability due to the blood–brain barrier may impair the response of glioblastoma to checkpoint inhibitor therapy.

Despite all of this, there are several studies that have demonstrated the potential benefit of neoadjuvant anti-PD1 immunotherapy in patients with glioblastoma. One study demonstrated that neoadjuvant pembrolizumab, in addition to adjuvant therapy following surgery, had prolonged OS compared to patients who received post-surgical therapy alone and also had increased T-cell expression and PD-L1 induction in the tumor microenvironment [88]. Another phase II trial demonstrated that neoadjuvant followed by adjuvant nivolumab led to immunomodulatory effects with improved immune cell infiltration and TCR diversity [89]. One should keep in mind that the studies demonstrating this benefit have all been relatively small in size. However, proof of principle exists. Neoadjuvant anti-PD1 immunotherapy has also shown promising results in other solid tumors, particularly in melanoma [90]. High rates of both radiographic and pathologic response with the neoadjuvant addition of nivolumab to anti-CTLA-4 inhibition (ipilimumab) in patients with melanoma have been demonstrated [91].

2.3. Targeting Regulatory T Cells and the Associated Immune Suppression Axis

The immunosuppressive tumor environment in GBM provides resistance to the anti-GBM immune response. Regulatory T cells (Tregs; CD4+ FoxP3+ CD25+) are regulatory T cells that promote and maintain the immunosuppressive tumor microenvironment [92] and can be activated by the immunosuppressive mediator, indoleamine 2,3 dioxygenase 1 (IDO1) [93]. GBM-cell IDO1 promotes tumorigenesis and increases immunosuppressive Treg recruitment while simultaneously decreasing cytotoxic CD8+ T-cell frequency, as shown in Figure 3 [94]. IDO1 expression is correlated with increasing tumor grade, as well as the expression of other immunosuppressive mediators such as PD-L1 [95]. Furthermore, glioma patients with upregulated intratumoral IDO1 expression have shorter OS when compared to those with intermediate and downregulated IDO expression (44.3 vs. 34 vs. 24.9 months) [95]. Interestingly, animal studies demonstrate that the genetic ablation of IDO1 by glioma cells results in decreased Treg recruitment [95] and significantly improved
survival rates (150 days vs. 26.5 days in IDO1-competent GBM mice, \( p < 0.002 \)) [95], pharmacological IDO1 enzyme inhibitors fail to recapitulate the same effect [96]. However, when IDO1 enzyme inhibition is used in combination with concurrent radiation and PD-1 mAbs, there is a synergistic improvement in the mOS [96]. This combination therapy also increased the CD8+ T cell: Treg ratio and provided long-lasting tumor control in 30–40% of mice with GBM [96]. Newer research has demonstrated that advanced age itself not only worsens the prognosis for GBM patients but can also suppress the efficacy of immunotherapies [96,97]. A phase 1 trial evaluating the combination of IDO1 inhibition with BMS-986205, PD-1 blockade with nivolumab, and concurrent radiotherapy with vs. without TMZ is currently underway [98].

**Figure 3.** IDO1 promotes the immunosuppressive tumor microenvironment through multiple mechanisms. ↑↑, ↑↑↑ = increased, ↓ = decreased.

IDO1 (indoleamine 2,3 dioxygenase 1) promotes the immunosuppressive tumor microenvironment through multiple mechanisms, including activation of MDSCs (myeloid-derived suppressor cells), Tregs (regulatory T cells), and M2 tumor-associated macrophages, while decreasing recruitment of NK (natural killer) cells and cytotoxic CD8+ T cells.

Another Treg targeting therapy is agonistic antibody treatment against glucocorticoid-induced TNFR-related protein (GITR). Agonism of the GITR receptor has shown preclinical efficacy in a number of GBM models by either depleting or reprogramming Tregs [99–101]. This is currently being tested in the context of stereotactic radiotherapy and anti-PD1 administration in recurrent GBM (NCT04225039). Of note, Tregs are not a dominant mechanism of immune suppression in GBM, and many tumors lack any appreciable infiltration of this population [102].
2.4. T-Cell Activators

While checkpoint inhibitors and Treg targeted therapies are certainly the most widely examined immunotherapeutic, a newer class of T-cell activators is being explored in clinical studies of GBM. One phase 1/1b study uses an agonistic antibody against the T-cell co-activator 41BB (PF-05082566) in conjunction with CCR4 blockade for GBM and other solid tumors [103,104]. OX-40 ligand (OX-40L) is another T-cell activator being explored. In an ongoing phase 1 trial (NCT03714334), the oncolytic adenovirus DNX-2240, which encodes for OX-40L, will be administered to recurrent GBM patients. A third T-cell co-activator being targeted is the CD40/CD40L axis. An Fc-engineered CD40 agonist antibody (2141-V11) will be administered in combination with the EGFRvIII immunotoxin (D2C7-IT) in recurrent GBM patients in one phase I study (NCT04547777) [105]. All of these trials are still in their infancy, with results expected over the next few years.

In summation, while targeting or enhancing T-cell activity is the largest avenue of immunotherapy clinical research in GBM, the inherent resistance of these tumors to immunotherapy may provide another hurdle to their successful use in patients. A summary of ongoing clinical trials investigating regulatory T cells and T-cell activators for glioblastoma is listed in Table 4.

Table 4. Treg and T-cell activator clinical trials for GBM.

| Target | Study Title | Phase | Size | Intervention | Primary Outcome | Reference |
|--------|-------------|-------|------|--------------|-----------------|-----------|
| TReg Targeting | A Phase 1/2a Study of IDO1 Inhibitor (BMS-986205) Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors | 1 | 30 | IDO1 inhibitor (BMS 986205) + RT + nivolumab with vs. without TMZ | MTD | NCT04047706 |
| GITR | A Phase II Study of the Anti-GITR Agonist INCAGN1876 and the PD-1 Inhibitor INCMGA00012 in Combination With Stereotactic Radiosurgery in Recurrent Glioblastoma | 2 | 32 | Anti-GITR agonist (INCAGN1876) + PD1 inhibitor (INCMGA00012) + SRS with vs. without surgery | Objective radiographic response | NCT04225039 |
| 41BB | A Phase 1b Study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors | 1/1b | 24 | Utomilumab (PF-05082566) + CCR4 mAb | MTD | NCT02444793 |
| OX-40L | Phase I Trial of DNX-2440 Oncolytic Adenovirus in Patients With Recurrent Glioblastoma | 1 | 24 | DNX-2440 virus | MTD | NCT03714334 |
| CD40L | A Phase I Trial of D2C7-IT in Combination With an Fc-engineered Anti-CD40 Monoclonal Antibody (2141-V11) Administered Intratumorally Via Convection-Enhanced Delivery for Adult Patients With Recurrent Malignant Glioma | 1 | 8 | CD40 agonist antibody (2141-V11) + EGFRvIII immunotoxin (D2C7-IT) | MTD | NCT04547777 |

Treg = regulatory T cell; IDO1 = indoleamine 2,3 dioxygenase 1; CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; RT = radiation therapy; TMZ = temozolomide; GITR = glucocorticoid-induced TNFR-related protein; PD-1 = programmed death-1; SRS = stereotactic radiosurgery; CCR4 = C-C chemokine receptor type 4; CD40L = cluster of differentiation 40 ligand; EGFRvIII = epidermal growth factor receptor variant III; MTD = maximum tolerated dose.

3. Clinical Factors That Prevent Immunotherapeutic Efficacy in GBM

There are numerous GBM-intrinsic factors and SOC treatment-associated factors that influence the efficacy of immunotherapy. Temozolomide (TMZ), an SOC alkylating chemotherapy, induces leukopenia, and specifically, lymphopenia [106]. The risk increases with steroid usage and concomitant use of radiation [1]. Treatment-associated lymphopenia can persist for up to one year and subsequently dampen the effect of subsequent immunotherapies [107]. Furthermore, the dose of alkylating therapy or route of administration may play a critical role in immunotherapeutic outcomes [108,109].

Surgical management also impacts the response to immunotherapy. The reduced number of glioblastoma tumor cells that remain after gross total resection may result in fewer tumor antigens and, consequently, a less robust immune response. Furthermore,
SOC treatments also have the potential to select aggressive tumor cell lines after targeting the less resistant cells, which can negatively impact the response to immunotherapies. Additionally, dexamethasone, a commonly used drug for treating symptomatic vasogenic edema, impairs proinflammatory CD8+ T-cell responses in GBM patients, thus contributing to a weakened immune response. Treatments such as surgery or radiation have also been shown to activate a host of immunosuppressive feedback loops [110] that may lead to a more pronounced degree of immunosuppression than can be observed prior to therapeutic intervention [1].

Intratumoral heterogeneity remains one of the most difficult impediments for glioblastoma therapies to overcome. Using single-cell RNA sequencing, it has been demonstrated that a single primary glioblastoma consists of a heterogeneous milieu of cells from a variety of different subgroups [111]. This intratumoral variability exists on both a temporal and spatial level, the latter of which highlights the risk of sampling error with a single regional biopsy [112] and has implications for both biomarker identification as well as therapeutic response. While treatment may be highly successful in eradicating one subclone, it may be unable to address the various other cellular subpopulations and, furthermore, may select subpopulations that become resistant to subsequent therapy [113–116]. Intratumoral heterogeneity highlights the potential need for multimodal, combinatorial therapies for glioblastoma.

In contrast, some aspects of SOC treatment may be beneficial with respect to immunotherapeutic approaches. For example, radiotherapy promotes effector T-cell mobilization into tumors and can help suppress the proliferation of immunosuppressive regulatory T cells. Furthermore, tumor cell death from radiotherapy can increase the exposure to a larger amount of immunostimulatory antigens to promote an immune response [1,117–119]. Of note, due to the location and nature of the disease, it is not feasible to obtain tumor tissue samples from all timepoints of interest. In turn, our understanding of the temporal immunologic picture of the tumor and its microenvironment is incomplete [120].

4. Predictive Biomarkers of Immunotherapeutic Efficacy

Numerous potential predictive biomarkers for response to immunotherapies in GBM have been investigated. These include: PD-L1 expression, tumor mutational burden (TMB), PTEN and MAPK pathway mutations, as well as the replication stress response (RSR). These are summarized in Table 5. A limitation to these biomarker analyses, alluded to above, is a lack of understanding of the optimal timepoints in the disease course for these to be assessed for validation. It is likely that different biomarkers, if valid, will have distinct predictability at specific disease course timepoints.

4.1. PD-L1 Expression

PD-L1 expression has been shown to impact the response to immunotherapies in several solid cancers such as melanoma and non-small-cell lung cancer, where PD-L1 expression on these tumor cells (i.e., presence of target) was shown to be associated with objective treatment response to PD-1 inhibition [121,122]. Expression of PD-L1 in GBM is heterogeneous, and higher expression is correlated with significantly shorter survival [91]. However, the expression of PD-L1 does not appear to be strongly predictive of response to immunotherapy in GBM patients. In addition, there is a lack of association between PD-1/PD-L1 expression and the tumor mutational burden of glioblastoma tumors [123].

4.2. Tumor Mutational Burden

Tumor mutational burden (TMB) refers to the total number of mutations within the genome of a tumor cell [123]. Increased TMB can be associated with increased prevalence of immunogenic epitopes of tumor cell surfaces, which, in theory, could improve response to immunotherapy [123,124]. However, not all mutations, including those for genes encoding intracellular proteins, are immunogenic, and the TMB may be heterogeneous between
tumor cells. Finally, there may be aspects intrinsic to the tumor microenvironment, which may supersede the importance of the TMB and immunogenic epitope expression.

Increased TMB has been previously shown to be associated with an improved response to PD-1 blockade in several cancer types [124]. However, recent studies demonstrated that high TMB in glioblastoma is not broadly predictive of response to immune checkpoint blockade and that samples taken from tumors responsive to anti-PD1 therapy do not have a higher rate of somatic mutations [125,126]. In one study, hypermutated glioma patients treated with PD-1 blockade had similar PFS and OS times compared to patients with non-hypermutated gliomas [127]. Additionally, patients with hypermutated gliomas treated with PD-1 blockade have shorter mOS compared to historical controls treated with other systemic agents [127]. Taken together, these results are suggestive that, in contrast to other cancers, GBM TMB plays a minimal role in response to immunotherapy and, in fact, may negatively impact the response. It appears that an elevated neoantigen load may need to be accompanied by increased immune infiltration for this type of approach to be effective [128]. Of note, there are case reports of germline mutations in DNA repair enzymes in brain tumor patients that were associated with favorable responses to immune checkpoint inhibition, presumably due to an increased TMB [129,130]. However, the elevation of TMB from germline mutations does not necessarily equate to a more homogeneous presence of specific mutations. These results are not generalizable to all glioblastoma patients, as the overwhelming majority of patients with brain tumors due not harbor germline DNA repair enzyme mutations.

4.3. PTEN Mutations

PTEN, a negative regulator of the PI3K/Akt pathway, has long been known to be a key contributor to the immunosuppressive microenvironment of GBM [131]. PTEN mutations in GBM also appear to be associated with a reduced response to anti-PD-1 therapy. PTEN mutations have been shown to occur more frequently in non-responders to PD-1 blockade as opposed to responders [126]. Furthermore, PTEN mutations may help to promote an immunosuppressive microenvironment by increasing tumor cell clustering that impedes immune cell infiltration, as well as increased expression of CD44, a cell surface adhesion receptor that facilitates cell interactions with the extracellular matrix. This results in increased tumor cell migration [126]. This corroborates findings from prior melanoma studies demonstrating that a loss of PTEN expression results in increased immunosuppressive cytokine expression, decreased T-cell infiltration, and subsequent decreased T cell-mediated cell death [132].

It should be noted that a large majority of glioblastomas exhibit chromosome 10q deletion, which is where the PTEN gene is located [133,134]. Thus, loss of PTEN expression and function as a result of chromosome 10q deletion, as opposed to PTEN mutation, likely contributes to the lack of therapeutic response in many glioblastomas.

4.4. MAPK Pathway Aberrancies

On the other hand, MAPK pathway mutations (including BRAF and PTPN11) in GBM are associated with an improved response to PD-1 blockade, defined in one study as either stable or shrinking GBM volume on imaging or a minimal amount of tumor cells in tissue samples [126]. In this study, GBM patients who were responsive to anti-PD-1 therapy had a significantly higher rate of BRAF and PTPN11 mutations compared to non-responders [126]. These mutations are known to drive MAPK/ERK pathway signaling, which results in an end product of ERK1/2 phosphorylation (p-ERK) [135]. Though BRAF/PTPN11 mutations were highly enriched in the responder patients to PD-1 blockade, only 30% of these patients had such mutations. Recently, we showed that phosphorylation of ERK1/2 (pERK), a downstream effector of MAPK, is present and elevated in all responders to PD1 blockade and in those that had prolonged survival following this form of immunotherapy [136]. Yet, not all patients with elevated pERK had long-term survival following this form of immunotherapy. The correlation between pERK with survival following PD-1 blockade...
was observed in two independent patient cohorts [136]. Responder patients that had elevated pERK included those without BRAF/PTPN11 mutations. In addition, increased p-ERK resulted in a higher number of myeloid cells and microglia expressing MHC-II in the tumor microenvironment, suggesting a proinflammatory effect [136]. It is uncertain if this may apply to other immunotherapeutic approaches. Interestingly, preclinical glioma models have shown that gliomagenesis in the absence of CD8 T cells leads to an increase in pERK in the tumors [137]. This may suggest that tumor-targeting immune infiltrates may facilitate the over-activity of immunosuppressive negative feedback loops.

4.5. Replication Stress Response

A new focus of the investigation has been the replication stress response (RSR), which is used by cells to slow DNA replication when replication stress, such as DNA lesions or limited nucleotides, occurs and requires repair [138]. Utilizing murine breast cancer models, one study demonstrated that gene expression of RSR defects (RSRDs) not only led to the accumulation of immunostimulatory cytosolic single-stranded DNA and promoted dendritic and T-cell infiltration but also was predictive of immune checkpoint blockade (ICB) response. The RSRD score was shown to be generalizable across tumor subtypes and was found to be a predictive and specific biomarker for clinical response to ICB in GBM patients [139].

Table 5. Studies investigating factors affecting checkpoint inhibitor response in glioblastoma.

| Predicted Response to Checkpoint Blockade | Target | Authors | Primary Results | PMID |
|-----------------------------------------|--------|---------|----------------|------|
| No effect                               | PD-L1 expression | Hodges et al. | There is no association between tumor mutational load and PD-1/PD-L1 expression ($p = 0.7699$, $p = 0.8237$) | 28371827 [123] |
| No effect/negative response             | Tumor mutational burden | McGrail et al. | Gliomas with high TMB had a low ORR (15.3%, 95% CI 92–23.4). ICB-treated glioma patients had worse OS vs. those treated with other modalities ($p = 0.23 \times 10^{-3}$) | 33736924 [125] |
| Negative response                       | PTEN mutations | Zhao et al. | PTEN mutations occur more frequently in non-responders to PD-1 blockade vs. responders ($p = 0.0063$, OR = 8.5) | 30742119 [126] |
| Improved response                       | MAPK pathway mutations | Zhao et al. | MAPK pathway alterations (PTPN11, BRAF) are enriched in responders to PD-1 inhibitors ($p = 0.019$, OR = 12.8) | 30742119 [126] |
|                                        | Replication stress response defects (RSRD) | McGrail et al. | RSR defects lead to immunostimulatory cytosolic ssDNA and improved ICB response ($p = 0.00019$ in breast cancer model, $p < 0.1 \times 10^{-3}$ in GBM cohort) | 34705519 [139] |

MAPK = mitogen-activated protein kinase; RSRD = replication stress response defects; PD-1 = programmed death 1; PD-L1 = programmed death ligand 1; TMB = tumor mutational burden; GBM = glioblastoma; PTEN = phosphatase and tensin homolog; OS = overall survival; PFS = progression-free survival; HR = hazard ratio; OR = odds ratio; ORR = overall response rate; ICB = immune checkpoint blockade.

5. Making Things Hot: Promoting T-Cell Infiltration into GBM

Glioblastomas are immunologically “cold” tumors that promote an overall immunosuppressive tumor microenvironment with few lymphocyte infiltrates and impaired antigen presentation [140]. These changes help explain why glioblastomas respond poorly to checkpoint inhibitors. In addition, when infiltrates occur, as suggested above, they may overactivate innate immunosuppressive systems at times. Several studies are now aimed at converting “cold” glioblastomas into ones that are “hot.” We have summarized some of these studies in Table 6.
Table 6. Clinical trials aimed at enhancing immunotherapeutic response in GBM.

| Primary Mechanism | Study Title                                                                 | Phase | Size | Intervention                                  | Primary Outcome                                      | Reference          |
|-------------------|----------------------------------------------------------------------------|-------|------|-----------------------------------------------|-----------------------------------------------------|--------------------|
| **STING agonism** | Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma | Preclinical | 6    | STING agonist IACS-8779                        | MTD and radiographic response                         | N/A                |
| **STAT3 inhibition** | A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma | 1     | 8    | p-STAT3 inhibitor WP1066                       | MTD. mOS = 25 mo.                                    | NCT02977780        |
| **IL-12 therapy** | An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroperoration (EP) in Combination With newly Diagnosed Glioblastoma (GBM) | 1/2   | 52   | INO-9012 (IL-12 plasmid) and INO-5401 + cemiplimab + TMZ + radiation | Safety (ongoing)                                      | NCT03491683        |
| **BBB disruption** | A Study to Evaluate the Safety of Transient Opening of the Blood-Brain Barrier by Low Intensity Pulsed Ultrasound With the SonoCloud Implantable Device in Patients With Recurrent Glioblastoma Before Chemotherapy Administration | 1/2   | 21   | SonoCloud + carboplatin                        | Safety. mPFs = 4.11 mo, mOS = 12.94 mo              | NCT02253212        |
| **BBB disruption** | A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in the Treatment of Brain Tumours With Doxorubicin | 1     | 5    | ExABlate                                      | Safety                                              | NCT0243991         |
| **BBB disruption** | A Study to Evaluate the Safety and the Efficacy of Transient Opening of the Blood-Brain Barrier (BBB) by Low Intensity Pulsed Ultrasound With the SonoCloud-9 Implantable Device in Recurrent Glioblastoma Patients Eligible for Surgery and for Carboplatin Chemotherapy | 1/2a  | 33   | SonoCloud-9 device + carboplatin               | MTD and BBB opening (ongoing)                        | NCT03744026        |
| **BBB disruption** | Phase I/II Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Alumabim-bound Paclitaxel in Patients With Recurrent Glioblastoma | 1/2   | 17   | SonoCloud-9 device + paclitaxel + carboplatin  | Maximum tolerated dose and 1-year survival rate (ongoing) | NCT04528680        |

STING = stimulator of interferon genes; STAT3 = signal transducers and activators of transcription 3; IL-12 = interleukin-12; BBB = blood–brain barrier; GBM = glioblastoma multiforme; TMZ = temozolomide; MTD = maximum tolerated dose; mOS = median overall survival; mPFS = median progression-free survival. * = secondary endpoint.

5.1. Oncolytic Viral Therapies

Oncolytic viral therapy uses viruses to selectively target tumor cells and subsequently induce tumor lysis, promote antigen presentation, recruit tumor-infiltrating lymphocytes, and activate the innate immune response [141–143]. A total of over 15 DNA and RNA virus species are currently being studied in glioma, including adenovirus, parvovirus, enterovirus, and herpes simplex virus-1 (HSV-1), among others [144]. Recently, after being studied in a phase II trial, one genetically engineered oncolytic virus based on HSV-1 (G47D) (Delytact/Teserpaturev) was conditionally approved for the treatment of malignant glioma in Japan. Additional details on current research involving oncolytic viral therapy are well summarized separately [144,145].

5.2. STING Agonism

STING (stimulator of interferon genes) agonists, through IFN-b and cytokine production, promote T-cell infiltration into the tumor microenvironment and thus have been of key interest in recent studies aimed at improving immunotherapeutic responses to checkpoint inhibitors [146–149]. A recent study demonstrated that intratumoral administration of a STING agonist (IACS-8779) in canines with glioblastoma was feasible, safe, and resulted in
a dose-dependent radiographic response [150]. These promising results warrant further investigation in additional translational studies.

5.3. STAT3 Signaling

Signal transducers and activators of transcription 3 (STAT3) is an intracellular cell signaling molecule that is highly expressed and constitutively activated in a variety of malignancies, including GBM [151]. STAT3 activation promotes the production of factors such as IL-10, IL-23, and TGF-β, which results in the accumulation of immunosuppressive cells such as regulatory T (Treg) cells, M2 tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSC), as well as the inhibition of dendritic cell development, ultimately promoting the immunosuppressive tumor microenvironment [151,152] as shown in Figure 4. As a result, STAT3 has become an emerging target for immunotherapy.

Several drugs targeting STAT3 activation, either through upstream kinase inhibition via JAK1/2 targeting (sorafenib, AG490, SAR317461) or through blocking of STAT3 phosphorylation (oleanolic acid, embelin), have been developed. Preclinical studies have demonstrated that these drugs decrease the proliferation, migration, and angiogenesis of glioblastoma cells and promote cytokine release for an improved immune response [153–155]. One study demonstrated that the STAT3 inhibitor WP1066 induced immunostimulatory cytokine release to promote T-cell effector function in murine models while also decreasing tumor-mediated immunosuppressive mechanisms of Treg and M2 macrophage accumulation [155]. WP1066 is now being evaluated in clinical trials, including for pediatric patients (NCT04334863), and has been shown to be well tolerated in human subjects in doses of 8 mg/kg, which exceeds the amount needed for conducting phase II studies in combination with radiation therapy [156]. The combination of radiation and STAT3 blockade with WP1066 in preclinical models markedly influenced the TME by inducing DC and T-cell infiltration within the tumor [157]. Ultimately, these results highlight how STAT3 antagonism can alter the immunosuppressive tumor microenvironment and subsequently improve the antitumor immune response.

STAT3 (signal transducers and activators of transcription 3) promotes the immunosuppressive tumor microenvironment through multiple mechanisms, including increased secretion of IL-10 and IL-23 (interleukin-10 and interleukin-23), MDSCs (myeloid-derived suppressor cells), and M2 tumor-associated macrophages, as well as inhibiting the development of dendritic cells. Recently studied methods of targeting STAT3 activation include inhibiting JAK1/2, as well as blocking the STAT3 phosphorylation.
5.4. Cytokine Therapies

Interleukin-12 (IL-12) has also been an important immune-activating cytokine under investigation as a form of immunotherapy for glioblastomas. Preclinical and clinical studies have shown that IL-12-based gene therapy can lead to safe and effective expression of this potent cytokine in gliomas and in the peri-tumoral brain [158–161]. IL-12 is known to help mediate both natural and adaptive immunity, increasing the production of interferon-y (IFN-y) as well as CD8+ T-cell production [161–166]. Previous studies investigating IL-12 therapy were limited due to toxicity and tolerability. However, recent studies have turned toward using a viral vector gene therapy with a ligand-inducible expression switch to help control IL-12 production in the local environment. Veledimex (VDX) is an activator ligand designed to promote the production of IL-12. A phase 1 trial demonstrated that VDX administration resulted in a dose-dependent increase in both IL-12 and IFN-y serum concentrations in patients with high-grade gliomas. Additionally, tissue analysis after treatment demonstrated a 17-fold increase in CD3+ T cells, as well as increases in CD8+ T cells, PD-1 expressing immune cells, and PD-L1 expressing cells. Preliminary analyses demonstrated a positive association between VDX dose and OS ($p = 0.0004$). These results indicate that IL-12 therapy helps transform an immunologically “cold” tumor microenvironment into a proinflammatory “hot” environment with an increased influx of immune cells [159]. IL-12 is incorporated in another multifaceted approach using synthetic DNA plasmids currently undergoing investigation in newly diagnosed glioblastoma (NCT03491683) [167].

5.5. Disrupting the Blood–Brain Barrier to Enhance Immunotherapy

Drug delivery into the CNS is notoriously difficult due to the protective blood–brain barrier (BBB), which provides another explanation for why so many investigated therapies for recurrent GBM have failed.

BBB disruption can occur with radiation therapy. Prior studies have demonstrated that low dose radiation up to 20–30 Gray can alter the integrity of the BBB and improve the permeability to certain therapeutic drugs [168]. One group demonstrated that CSF concentrations of methotrexate increased three-fold after irradiation therapy [169]. However, studies have now shifted more toward using ultrasound as a method of disrupting the BBB.

The combination of pulsed ultrasound and intravenous microbubble injection has been shown to be a safe, minimally invasive, well-tolerated, and reversible method of disrupting the BBB [170]. Two major strategies have been implemented to deliver US-based BBB disruption: an extracranial device that delivers focused ultrasound called the ExAblate system and an implantable ultrasound device called the SonoCloud. Both have been studied in multiple preclinical and clinical trials [170–173]. A newer version of the SonoCloud, called the SonoCloud-9, is comprised of nine transducers on an implantable grid and is designed to cover a larger resection area. It is currently being studied in a multicenter phase 1/2a clinical trial [174].

Several studies have investigated the impact of US-mediated BBB disruption on drug delivery to the CNS. Due to its poor CNS penetration despite robust in vitro anti-glioma effects, the microtubule-stabilizing agent paclitaxel was recently of particular interest. The combination of US-based BBB disruption followed by an albumin-bound formulation of paclitaxel (Abraxane) not only led to a significant 3–5-fold increase in paclitaxel concentration at multiple time points compared to non-sonicated controls but also improved mOS compared to Abraxane only (35 vs. 31 days, 0.0036) [175]. US-based BBB disruption, therefore, can both enhance CNS penetration of PTX and improve survival [176]. Additionally, paclitaxel has been recently identified as an inducer of immunogenic cell death, a form of cell death that directly promotes antitumor immunity [176], and as a result, BBB-mediated delivery of paclitaxel may enhance immunotherapies for GBM [177].

Animal model studies have examined the impact of low-intensity pulsed ultrasound (LIPU) on various drug efficacies. In mice, the addition of LIPU to anti-PD 1 therapy resulted in a longer mOS compared to anti-PD 1 therapy alone (58 vs. 39 days, respectively), though it did not reach significance [178]. Mice treated with both LIPU and CAR T-cell
therapy had significantly increased CNS CAR T-cell delivery and longer mOS compared to CAR T-cell therapy alone. Furthermore, the addition of LIPU to an APC-based therapy demonstrated a significantly increased deposition of CXCL10-secreting APCs in the tumor microenvironment, as well as enhanced survival ($p < 0.05$) [178].

6. Harnessing the Innate Immune System for GBM Immunotherapy

The innate immune system, which constitutes our first line of defense, mediates broad responses against pathogens while also activating adaptive immunity for more specific targeting. Research has now shifted additional attention to methods of modulating the innate immune system for the treatment of glioblastoma. Recent glioblastoma clinical trials focused on the innate immune system are listed in Table 7.

Table 7. Immunotherapy clinical trials aimed at the innate immune system for GBM.

| Target | Study Title | Phase | Size | Intervention | Primary Outcome | Reference |
|--------|-------------|-------|------|--------------|----------------|-----------|
| MDSC   | Targeting Myeloid Derived Suppressor Cells in Recurrent Glioblastoma: Phase 0/1 Trial of Low Dose Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | 0/1   | 4    | Capecitabine + bevacizumab | MDC reduction ranging between 20% and 79% from baseline | NCT02669173 |
|        | A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors | 1/2   | 146  | CSF1R inhibitor (BLZ945) with vs. without PD1 blockade (PDR001) | MTD, 6 mo PFS | NCT02829723 |
|        | A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma | 2     | 38   | CSF1R inhibitor (PLX3397) | 6 mo PFS = 8.6% | NCT01349036 |
| Niacin (ongoing) | A Phase I-II Study of Niacin in Patients With Newly Diagnosed Glioblastoma Receiving Concurrent Radiotherapy and Temozolomide Followed by Monthly Temozolomide | 1/2   | 59   | Niacin + RT + TMZ | MTD, 6 mo PFS | NCT04677049 |
| Gamma delta cells (ongoing) | A Phase I Study of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified γδ T Cells in Patients With Newly Diagnosed Glioblastoma Multiforme Receiving Maintenance Temozolomide Chemotherapy | 1     | 12   | Gene-modified gamma delta T cells | MTD | NCT04165941 |

MDSC = myeloid-derived suppressor cells; PD1 = programmed death 1; CSF1R = colony-stimulating factor 1 receptor; RT = radiation therapy; TMZ = temozolomide; PFS = progression-free survival; MTD = maximum tolerated dose.

6.1. Tumor-Infiltrating Myeloid Cells

Tumor-infiltrating myeloid cells are the most abundant cellular infiltrates in GBM [179,180], which can sometimes comprise up to 50% of the tumor mass [179]. These heterogeneous groups of cells are interchangeably given names such as: myeloid-derived suppressor cells (MDSC), monocyte-derived macrophages (MDM), tumor-associated macrophages (TAM), and tumor-associated myeloid cells (TAMC). They have become an incredibly attractive target for GBM immunotherapy due to their central role in promoting immunosuppression in GBM [181–183]. MDSCs can be subdivided into monocyic stem cells (mMDSC) versus granulocytic stem cells (gMDSC), which have distinct sex-dependent roles in GBM pathogenesis. Recent research has shown that mMDSCs accumulate intratumorally and promote GBM progression in males, whereas gMDSCs accumulate peripherally and primarily regulate immune suppression in females [184]. While large trials of immunotherapies for glioblastoma have thus far not demonstrated any clear sex-based differences in outcomes, it is possible that this may still prove to be of importance as we explore immunotherapeutic management of glioblastoma.

There are two main methods of myeloid targeting in GBM. The first involves depleting or preventing the recruitment of cells to the tumor site, and the second involves “reprogramming” these cells to become immunostimulatory (Figure 5).
Figure 5. MDSCs can be targeted through various mechanisms. MDSCs (myeloid-derived suppressor cells) promote an immunosuppressive tumor microenvironment. Two main methods of targeting MDSCs include (1) inhibiting MDSC recruitment, such as with CCR2 (C-C chemokine receptor 2) blockade, as well as DFMO (difluormethylornithine) administration, and (2) reprogramming MDSCs to become immunostimulatory, such as with CSF1R (colony-stimulating factor 1 receptor) inhibition and niacin administration.

Approaches that deplete myeloid cells from GBM have shown potential in preclinical studies of GBM. One study showed that nanoparticle-mediated targeting of myeloid cells using PD-L1 antibodies robustly depletes myeloid cells after radiation, leading to pronounced survival benefits [115]. Other studies have utilized blockade of CCR2 as a modality to prevent myeloid recruitment to the CNS [185]. Recent work has also identified that the metabolic inhibitor difluormethylornithine (DFMO) could be used to deplete myeloid cells from GBM and promote an inflammatory tumor microenvironment [186]. Clinically, a recent phase 0/1 trial utilized the natural sensitivity of MDSC to 5-Fluorouracil to deplete this population from the tumors of GBM patients [187].

Reprogramming myeloid cells to a more tumor supportive phenotype has gained attention by targeting the colony-stimulating factor 1 receptor (CSF1R). Pioneering preclinical work identified that pharmacological blockade of CSF1R using BLZ925 can promote the survival of animals with GBM [188], which can be used in combination with stereotactic radiotherapy for even more robust antitumor responses [189]. This led to a phase 1 exploration of BLZ945 in combination with PD-1 blockade for solid tumors (including GBM) [190]. Another CSF1R inhibitor, PLX3397 (pexidartinib), was tested in recurrent GBM and shown to be safe, though it did not result in any changes in OS [191]. Strategies to target this compartment in GBM are of continued interest to researchers but will likely need to be a component of a multi-agent regimen.

The presence of immunosuppressive macrophages has been a difficult hurdle to overcome in the attempts to develop effective immunotherapies for glioblastoma. Some recent work has focused on using niacin (vitamin B3) to stimulate the antitumor activity of macrophages and microglia. One study demonstrated that the exposure of monocytes to niacin resulted in increased levels of interferon-a14 for a subsequent anti-proliferative effect. Furthermore, preclinical work with niacin-treated mice with brain tumor-initiating cells led to increased monocyte and macrophage intratumoral infiltration, reduced tumor
size, and improved survival [192]. A phase I/II study studying the efficacy of niacin in addition to radiation and temozolomide is currently ongoing (NCT04677049).

6.2. NK Cells

Natural killer (NK) cells are characterized by the expression of CD16 and CD56 surface antigens and lack CD3/T-cell receptor molecules. In contrast to T cells, NK cells do not require antigen sensitization prior to killing targets [193]. Although NK cells can migrate into the GBM microenvironment, these tumor-infiltrating NK (TI-NK) cells are significantly altered in such a fashion that their cytotoxic function is impaired, allowing glioblastomas to evade NK cell targeting. NK cell dysfunction occurs through direct contact between glioblastoma stem cells and NK cells, which results in the av integrin-mediated release of TGF-β1. Preclinical studies have shown that inhibition of the av integrin/TGF-β1 axis can protect NK cell antitumor activity, and co-administration of NK cells with either TGF-β or av inhibitors resulted in improved OS in mice [194]. These results are overall suggestive of a promising new immunotherapy strategy for GBM patients.

6.3. Gamma Delta T Cells

Gamma delta (γδ) T cells play a role in both the innate and adaptive systems and are characterized by T-cell receptors comprised of one gamma and one delta chain, in contrast to other T cells with alpha and beta chains. Though they are primarily found in the gut mucosa, their role in impairing tumorigenesis has been an evolving area of interest [195]. Preclinical animal studies had previously demonstrated that γδ T cells have a cytotoxic effect on GBM cells [196–198]. When compared to control patients, one study demonstrated that GBM patients had a lower absolute γδ T-cell count and decreased γδ T-cell proliferation. Though tumor infiltration by γδ T cells may be hindered by the lymphodepletive effects of temozolomide, new studies have focused on modifying γδ T cells to be resistant to temozolomide. Preliminary results of a phase 1 trial investigating the combination of modified γδ T cells and temozolomide in new glioblastoma patients, known as drug-resistant immunotherapy, showed the combination therapy to be safe and feasible [199,200]. Further results are pending.

6.4. The Role of B Cells

Although most strategies for cancer treatments are focused on the adaptive immune system and specifically T cells, recent work has highlighted the potential role of B cells, which are involved in both the adaptive and innate immune systems. Intratumoral B cell infiltration is associated with a suitable prognosis in several solid tumors, such as melanoma [201,202], breast cancer [203], colorectal cancer [204], and non-small cell lung cancer (NSCLC) [205], and many others [206–208]. B cells that express the co-stimulatory marker 4-1BBL have been studied in GBM models. Signaling via 4-1BBL is associated with decreased T-cell death, enhanced T-cell proliferation, and improved immunological memory. 4-1BBL is expressed on CD4+ and CD8+ T cells as well as B cells. B cells that express 4-1BBL have been shown to enhance cytotoxic CD8+ T-cell response [209]. In one recent study, 4-1BBL+ B cells that were activated via CD40 and IFNγ stimulation (known as the BVax vaccine) were shown to have increased MHC-I and MHC-II surface expression for both CD8+ T-cell activation and antigen presentation as an APC. Furthermore, the combination of BVax + RT + TMZ + anti-PD-L1 therapy improved overall survival, resulted in tumor eradication in 80% of mice, and inhibited tumor recurrence after re inoculation. In early translational studies, BVax derived from GBM patients’ activated autologous CD8+ T cells have successfully killed autologous glioma cells in an antigen-specific manner. Overall, these results support further investigation in future translational studies [210].
7. Finding the Balance

The interplay between the immune system and glioblastoma is complex and influenced by a myriad of factors. Certain molecular factors that predict a favorable response to immunotherapies in non-CNS tumors paradoxically portend a worse response in glioblastoma. Thoughtful consideration of these factors can help guide our choice of various synergistic combination therapies that take advantage of the vast immune landscape in a multipronged approach. Therapies that both improve immunostimulatory responses against glioblastoma while decreasing the immunosuppressive response will likely be the most successful.

8. Conclusions

The prognosis for glioblastoma patients has unfortunately remained poor with our current SOC therapeutic options. Though immunotherapy has proved successful in treating other cancers, results in clinical trials for glioblastoma patients have been rather disappointing. Molecular factors influencing the response to immunotherapy have been extensively studied and should be incorporated in future translational and clinical studies. Additionally, other strategies for enhancing responses to immunotherapies, including promoting an immunostimulatory tumor environment and utilizing the innate immune system, should be areas of an increased focus to develop more effective immunotherapies for glioblastoma patients.

Author Contributions: Conceptualization, R.V.L.; resources, R.V.L., D.A.W., C.L.-C., J.M., A.M.S., A.B.H. and T.Q.C.; writing—original draft preparation, R.V.L. and T.Q.C.; writing—review and editing, R.V.L., D.A.W., C.L.-C., J.M., A.M.S., A.B.H. and T.Q.C.; supervision, R.V.L. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the following NIH grants: P30CA060553, NS110703, CA120813, NS120547, and P50CA221747.

Acknowledgments: We thank Lindsey Van for her assistance with the preparation of the manuscript for submission.

Conflicts of Interest: A.M.S. reports authorship of patents filed by Northwestern University regarding immunotherapy for gliomas. Research support has kindly been provided by BMS, Agenus, and Carthera. Additionally, he has received philanthropic support from Agenus. A.B.H. serves on the advisory board of Caris Life Sciences, and WCG Oncology Advisory Board receives royalty and milestone payments from DNattrix for the licensing of “Biomarkers and combination therapies using oncolytic virus and immunomodulation” (11,065,285) and is supported by research grants from Celularity, Codiak Biosciences, and AbbVie. Other support has been provided by Moleculin and Carthera, and she has received consulting fees in the last year from Novocure and Istarri Oncology. She additionally has active patents for “miRNA for treating cancer and for use with adoptive immunotherapies” (9,675,633) and “Concurrent chemotherapy and immunotherapy (9,399,662) with a patent pending for “Low intensity ultrasound combination cancer therapies” (International application #PCT/US2022/019435 and US 63/158,642). RVL serves on the scientific advisory board for Merck. Additionally, he is on the speakers’ bureau for Novocure and Merck. He receives research support from BMS. T.Q.C., D.A.W., C.L.C., and J.M. have no conflicts of interest to disclose.

References

1. Lukas, R.V.; Wainwright, D.; Ladomersky, E.; Sachdev, S.; Sonabend, A.M.; Stupp, R. Newly Diagnosed Glioblastoma: A Review on Clinical Management. *Oncology* 2019, 33, 91. [PubMed]
2. Lukas, R.V.; Mrugala, M.M. Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice. *Neuro-Oncol. Pr.* 2016, 4, 209–219. [CrossRef] [PubMed]
3. Waldman, A.D.; Fritz, J.M.; Lenardo, M.J. A guide to cancer immunotherapy: From T cell basic science to clinical practice. *Nat. Rev. Immunol.* 2020, 20, 651–668. [CrossRef]
4. Lim, M.; Weller, M.; Idiba, A.; Steinbach, J.; Finocchiaro, G.; Raval, R.R.; Ansstas, G.; Baehring, J.; Taylor, J.W.; Honnorat, J.; et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. *Neuro-Oncology* 2022. [CrossRef] [PubMed]
5. Omuro, A.; Brandes, A.; Carpentier, A.F.; Idbahi, A.; Reardon, D.; Cloughesy, T.; Sumrall, A.; Baehring, J.; Bent, M.V.D.; Bähr, O.; et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter. An international randomized phase III trial. Neuro-Oncology 2022. [CrossRef]

6. Reardon, D.A.; Desjardins, A.; Vredenburgh, J.J.; O’Rourke, D.M.; Tran, D.D.; Fink, K.L.; Nabors, L.B.; Li, G.; Bota, D.A.; Lukas, R.V.; et al. Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): Results of a double-blind randomized phase II trial. Clin. Cancer Res. 2020, 26, 1586–1594. [CrossRef]

7. Ayasoufi, K.; Pfaller, C.K.; Evgin, L.; Khadka, R.H.; Tritz, Z.P.; Goddery, E.N.; Fain, C.; Yokanovich, L.T.; Himes, B.T.; Jin, F.; et al. Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators. Brain 2020, 143, 3629–3652. [CrossRef]

8. Chongsaithidkiet, P.; Jackson, C.; Koyama, S.; Loebel, F.; Cui, X.; Farber, S.H.; Woroniecka, K.; Elsamadicy, A.A.; DeChant, C.A.; Kemeny, H.R.; et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 2018, 24, 1459–1468. [CrossRef]

9. Bloch, O.; Crane, C.A.; Kaur, R.; Saafae, M.; Rutkowski, M.J.; Parsa, A.T. Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages. Clin. Cancer Res. 2013, 19, 3165–3175. [CrossRef]

10. Ullén, H.; Blom, U.; Blomgren, H.; von Holst, H. Blood lymphocyte subsets in patients with primary intracranial tumours. Correlation to histological tumour type and anatomical site. Acta Neurochir. 1986, 81, 100–105. [CrossRef]

11. Bodmer, S.; Strommer, K.; Frei, K.; Siepl, C.; De Tribolet, N.; Heid, I.; Fontana, A. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J. Immunol. 1989, 143, 3222–3229. [PubMed]

12. Dix, A.R.; Brooks, W.H.; Roszman, T.L.; Morford, L. Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunol. 1999, 100, 216–232. [CrossRef]

13. Land, C.A.; Musich, P.R.; Haydar, D.; Krencuite, G.; Xie, Q. Chimeric antigen receptor T-cell therapy in glioblastoma: Charging the T cells to fight. J. Transl. Med. 2020, 18, 1–13. [CrossRef] [PubMed]

14. Sayegh, E.T.; Oh, T.; Fakurnejad, S.; Bloch, O.; Parsa, A.T. Vaccine therapies for patients with glioblastoma. J. Neuro-Oncol. 2014, 119, 531–546. [CrossRef] [PubMed]

15. Batra, S.K.; Castelino-Prabhu, S.; Wikstrand, C.J.; Zhu, X.; Humphrey, P.A.; Friedman, H.S.; Bigner, D.D. Epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002, 62, 3335–3339. [PubMed]

16. Lai, A.; Glazer, C.; Martinson, H.; Friedman, H.S.; Archer, G.; Sampson, J.H.; Riggins, G.J. Mutant epidermal growth factor receptor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002, 62, 3335–3339. [PubMed]

17. Nagane, M.; Coufal, F.; Lin, H.; Bogler, O.; Cavenee, W.K.; Huang, H.J. A common mutant epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Expert Rev. Anticancer Ther. 2007, 7, 545–550. [CrossRef]

18. Heimberger, A.B.; Crotty, L.; Archer, G.; Hess, K.R.; Wikstrand, C.J.; Friedman, A.H.; Friedman, H.S.; Bigner, D.D.; Sampson, J.H. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res. 2003, 9, 4247–4254. [PubMed]

19. Heimberger, A.B.; Hatky, R.; Suki, D.; Yang, D.; Weinberg, J.; Gilbert, M.; Sawaya, R.; Aldape, K. Prognostic Effect of Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. J. Clin. Oncol. 2010, 28, 4722–4729. [CrossRef]
27. Weller, M.; Butowski, N.; Tran, D.D.; Recht, L.D.; Lim, M.; Hirte, H.; Ashby, L.; Mechtler, L.; Goldlust, S.A.; Iwamoto, F.; et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRVIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017, 18, 1373–1385. [CrossRef]

28. Sampson, J.H.; Aldape, K.D.; Archer, G.E.; Coan, A.; Desjardins, A.; Friedman, A.H.; Friedman, H.S.; Gilbert, M.R.; Herndon, J.E.; McLendon, R.E.; et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRVIII-expressing tumor cells in glioblastoma. Neuro-Oncology 2011, 13, 324–333. [CrossRef]

29. van den Bent, M.J.; Gao, Y.; Kerkhof, M.; Kros, J.M.; Gorlia, T.; Van Zwieten, K.; Prince, J.; Van Duinen, S.; Sillevis Smitt, P.A.; Taphoorn, M.; et al. Changes in the EGFR amplification and EGFRVIII expression between paired primary and recurrent glioblastomas. Neuro-Oncology 2015, 17, 935–941. [CrossRef]

30. Nobusawa, S.; Watanabe, T.; Kleihues, P.; Ohgaki, H. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clin. Cancer Res. 2009, 15, 6002–6007. [CrossRef]

31. Han, S.; Liu, Y.; Cai, S.J.; Qian, M.; Ding, J.; Larion, M.; Gilbert, M.R.; Yang, C. IDH mutation in glioma: Molecular mechanisms and potential therapeutic targets. Br. J. Cancer 2020, 122, 1580–1589. [CrossRef] [PubMed]

32. Platten, M.; Schilling, D.; Bunse, L.; Wick, A.; Bunse, T.; Kiehl, D.; Karapanagiotou-Schenkel, I.; Harting, I.; Sahm, F.; Schmitt, R.; et al. A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16). J. Clin. Oncol. 2018, 36, 2001. [CrossRef]

33. Kijima, N.; Hosen, N.; Kagawa, N.; Hashimoto, N.; Oji, Y.; Sugiyama, H.; Yoshimine, T. Wilms’ tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis. Anticancer Res. 2014, 34, 61–67.

34. Izumoto, S.; Tsuboi, A.; Oka, Y.; Suzuki, T.; Hashiba, T.; Kagawa, N.; Hashimoto, N.; Maruno, M.; Elisseeva, O.A.; Shirakata, T.; et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J. Neurosurg. 2008, 108, 963–971. [CrossRef] [PubMed]

35. Oji, Y.; Hashimoto, N.; Tsuboi, A.; Murakami, Y.; Iwai, M.; Kagawa, N.; Chiba, Y.; Izumoto, S.; Elisseeva, O.; Ichinohasama, R.; et al. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. Int. J. Cancer 2016, 139, 1391–1401. [CrossRef] [PubMed]

36. Takashima, S.; Oka, Y.; Fujiki, F.; Morimoto, S.; Nakajima, H.; Nakae, Y.; Nakata, J.; Nishida, S.; Hosen, N.; Tatsumi, N.; et al. Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine. Futur. Sci. OA 2016, 2, 5096. [CrossRef]

37. Fu, S.; Piccion, D.E.; Liu, H.; Lukas, R.V.; Kesari, S.; Areegawi, D.; Hong, D.S.; Yamaguchi, K.; Whicher, K.; Zhang, Y.; et al. A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. Sci. Rep. 2021, 11, 22355. [CrossRef] [PubMed]

38. Kawaniishi, Y.; Udaoka, K.; Yawata, T.; Nakai, E.; Fukuda, H.; Fukui, N.; Ueba, T. Imit-03 Clinical Trial For Newly Diagnosed Malignant Glioma With Wt1-W10 Vaccination. Neuro-Oncology Adv. 2019, 1, ii17. [CrossRef]

39. Cobbs, C.S.; Harkins, L.; Samanta, M.; Gillespie, G.Y.; Bharara, S.; King, P.H.; Nabors, L.B.; Cobbs, C.G.; Britt, W.J. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002, 62, 3347–3350.

40. Rahman, M.; Dastmalchi, F.; Mechtler, L.; Goldlust, S.A.; Iwamoto, F.; O’Brien, B.J.; et al. A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma patients to reveal a lack of immune effector function. OncoImmunology 2018, 8, e1514921. [CrossRef]

41. Lucas, K.G.; Bao, L.; Bruggeman, R.; Dunham, K.; Specht, C. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J. Neuro-Oncol. 2010, 103, 231–238. [CrossRef] [PubMed]

42. Batich, K.A.; Reap, E.A.; Archer, G.E.; Sanchez-Perez, L.; Nair, S.K.; Schmittling, R.J.; Norberg, P.; Xie, W.; Herndon, J.E.; II; Healy, P.; et al. Long-term Survival in Glioblastoma With Cytomegalovirus pp65-Targeted Vaccination. Clin. Cancer Res. 2017, 23, 1898–1909. [CrossRef] [PubMed]

43. Weathers, S.-P.S.; Penal-Prado, M.; Banerjee, P.P.; Bdiwi, M.; Shaim, H.; Alsluliman, A.; Shanley, M.; Long, J.; De Groot, J.F.; O’Brien, B.J.; et al. A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function. J. Clin. Oncol. 2018, 36, 2515. [CrossRef]

44. Smith, C.; Lineburg, K.E.; Martins, J.P.; Ambalavanhil, G.R.; Neller, M.A.; Morrison, B.; Matthews, K.K.; Rehan, S.; Crooks, P.; Panikkar, A.; et al. Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme. J. Clin. Invest. 2020, 132, 6041–6053. [CrossRef] [PubMed]

45. Batich, K.A.; Mitchell, D.A.; Healy, P.; Herndon, J.E., II; Sampson, J.H. Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. Clin. Cancer Res. 2020, 26, 5297–5303. [CrossRef] [PubMed]

46. Sampson, J.H.; Batich, K.A.; Gunn, M.D.; Huang, M.-N.; Sanchez-Perez, L.; Nair, S.K.; Congdon, K.L.; Reap, E.A.; Archer, G.E.; Desjardins, A.; et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015, 519, 366–369. [CrossRef]

47. Garg, H.; Suri, P.; Gupta, J.C.; Talwar, G.P.; Dubey, S. Survivin: A unique target for tumor therapy. Cancer Cell Int. 2016, 16, 1–14. [CrossRef]
49. Fenstermaker, R.A.; Ciesielski, M.J.; Qiu, J.; Yang, N.; Frank, C.L.; Lee, K.P.; Mechtler, L.R.; Belal, A.; Ahluwalia, M.S.; Hutson, A.D. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol. Immunother. 2016, 65, 1339–1352. [CrossRef]

50. Ahluwalia, M.; Peereboom, D.; Rauf, Y.; Schilero, C.; Ciolfi, M.; Ciesielski, M.; Fenstermaker, R. Phase II study of pembrolizumab plus SurVaxM for glioblastoma at first recurrence. Neuro-Oncology 2020, 22, ii34–ii35. [CrossRef]

51. Ciesielski, M.J.; Ahluwalia, M.S.; Reardon, D.A.; Abad, A.P.; Curry, W.T.; Wong, E.T.; Peereboom, D.M.; Figel, S.A.; Hutson, A.; Groman, A.; et al. Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma. J. Clin. Oncol. 2022, 40, 2037. [CrossRef]

52. Killela, P.J.; Reitman, Z.J.; Jiao, Y.; Bettgeowda, C.; Agrawal, N.; Diaz, L.A., Jr.; Friedman, A.H.; Friedman, H.; Gallia, G.L.; Giovannella, B.C.; et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. USA 2013, 110, 6021–6026. [CrossRef] [PubMed]

53. Lee, Y.; Koh, J.; Kim, S.-I.; Won, J.K.; Park, C.-K.; Choi, S.H.; Park, S.-H. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Acta Neuropathol. Commun. 2017, 5, 1–11. [CrossRef]

54. Arakawa, Y.; Yoshiko, O.; Yoshitaka, N. Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma. J. Clin. Oncol. 2021, 39, 2038. [CrossRef]

55. Wen, P.Y.; Reardon, D.A.; Armstrong, T.S.; Phuphanich, S.; Aiken, R.D.; Landolfi, J.C.; Curry, W.T.; Zhu, J.J.; Glantz, M.; Peereboom, D.M.; et al. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Newly Diagnosed GlioblastomaICT-107 Vaccine for Newly Diagnosed Glioblastoma. Clin. Cancer Res. 2019, 25, 5799–5807. [CrossRef] [PubMed]

56. Wick, W.; Idbaih, A.; Tabatabai, G.; Seiji, T.; Yoshinobu, T. Heat shock protein derivatives for delivery of antigens to antigen presenting cells. Sci. Immunol. 2015, 348, 69–74. [CrossRef]

57. Ott, P.A.; Hu, Z.; Keskin, D.B.; Shukla, S.A.; Sun, J.; Bozym, D.J.; Zhang, W.; Luoma, A.; Giobbie-Hurder, A.; Peter, L.; et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017, 547, 217–221. [CrossRef]

58. Carreno, B.M.; Magrini, V.; Becker-Hapak, M.; Kaabinejadian, S.; Hildebrand, W.H.; Mardis, E.R.; et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015, 348, 803–808. [CrossRef] [PubMed]

59. Sahin, U.; Derhovanessian, E.; Miller, M.; Klokke, B.-P.; Simon, P.; Lőwer, M.; Buhr, V.; Tadmor, A.D.; Luxemburger, U.; Schrôrs, B.; et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017, 547, 222–226. [CrossRef]

60. Keskin, D.B.; Anandappa, A.J.; Sun, J.; Tirosh, I.; Mathewson, N.D.; Li, S.; Oliveira, G.; Giobbie-Hurder, A.; Felt, K.; Gjini, E.; et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 2018, 565, 234–239. [CrossRef]

61. Liu, L.M.; Omofoye, O.A.; Rudnick, J.D.; Kim, S.; Dhooitour, M.; Phuphanich, S.; Wang, H.; Mazer, G.; Peereboom, D.; et al. First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J. Transl. Med. 2018, 16, 142. [CrossRef] [PubMed]

62. Hu, J.L.; Omofoye, O.A.; Rudnick, J.D.; Kim, S.; Dhooitour, M.; Phuphanich, S.; Wang, H.; Mazer, G.; Peereboom, D.; et al. A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent GlioblastomaA Study of Dendritic Cell Vaccine Patients with Glioblastoma. Clin. Cancer Res. 2022, 28, 689–696. [CrossRef] [PubMed]

63. Nishikawa, M.; Seiji, T.; Yoshinobu, T. Heat shock protein derivatives for delivery of antigens to antigen presenting cells. Int. J. Pharm. 2008, 354, 23–27. [CrossRef]

64. Bilich, O.; Crane, C.A.; Fuks, Y.; Kaur, R.; Aghi, M.K.; Berger, M.S.; Butowski, N.A.; Chang, S.M.; Clarke, J.L.; McDermott, M.W.; et al. Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: A phase II, single-arm trial. Neuro-Oncology 2014, 16, 274–279. [CrossRef]

65. Bilich, O.; Shi, Q.; Anderson, S.K.; Knopp, M.; Raizer, J.; Clarke, J.; Waziri, A.; Colman, H.; Bruce, J.; Olson, J.J.; et al. ATIM-14. Alliance A071101: A phase II randomized trial comparing the efficacy of heat shock protein peptide complex-96 (HSPPC-96) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma. Neuro-Oncology 2017, 19 (Suppl. 6), vi29. [CrossRef]

66. Galanis, E.; Wu, W.; Cloughesy, T.; Lamborn, K.; Mann, B.; Wen, P.Y.; Reardon, D.A.; Wick, W.; Macdonald, D.; Armstrong, T.S.; et al. Phase 2 trial design in neuro-oncology revisited: A report from the RANO group. Lancet Oncol. 2012, 13, e196–e204. [CrossRef]

67. Grossman, S.A.; Schreck, K.; Ballman, K.; Alexander, B. Point/counterpoint: Randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. Neuro-Oncology 2017, 19, 469–474. [CrossRef]

68. Sheikh, S.; Radivoyevitch, T.; Barnholtz-Sloan, J.S.; Vogelbaum, M. Long-term trends in glioblastoma survival: Implications for historical control groups in clinical trials. Neuro-Oncol. Pr. 2019. [CrossRef]

69. Liu, Y.; Carlsson, R.; Ambjørn, M.; Hasan, M.; Badn, W.; Darabi, A.; Siesjö, P.; Issazadeh-Navikas, S. PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients. J. Neurosci. 2013, 33, 14231–14245. [CrossRef] [PubMed]
71. Pardoll, D.M. The blockade of immune checkpoints in cancer immuno-therapy. Nat. Rev. Cancer. 2012, 12, 252–264. [CrossRef] [PubMed]

72. Binder, D.C.; Davis, A.A.; Wainwright, D.A. Immunotherapy for cancer in the central nervous system: Current and future directions. OncoImmunology 2015, 5, e1082027. [CrossRef] [PubMed]

73. Reardon, D.A.; Brandes, A.A.; Omuro, A.; Mulholland, P.; Lim, M.; Wick, A.; Baehring, J.; Ahluwalia, M.S.; Roth, P.; Bähr, O.; et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized trial. JAMA Oncol. 2020, 6, 1003–1010. [CrossRef] [PubMed]

74. Duerinck, J.; Schwarze, J.K.; Awada, G.; Tijtgat, J.; Vaeyens, F.; Bertels, C.; Geens, W.; Klein, S.; Seynaeve, L.; Cras, L.; et al. Intracerebral administration of CTLA-4 and PD-1 immunee checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: A phase I clinical trial. J. Immunother. Cancer. 2021, 9, e002296. [CrossRef]

75. Reardon, D.A.; Kim, T.M.; Frenel, J.; Simonelli, M.; Lopez, J.; Subramaniam, D.S.; Siu, L.L.; Wang, H.; Krishnan, S.; Stein, K.; et al. Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. Cancer 2021, 127, 1620–1629. [CrossRef]

76. Fukumura, D.; Kloepper, J.; Amoozgar, Z.; Duda, D.G.; Jain, R.K. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat. Rev. Clin. Oncol. 2018, 15, 325–340. [CrossRef]

77. Allen, E.; Jabouille, A.; Rivera, L.B.; Lodewijckx, I.; Missiaen, R.; Steri, V.; Feyen, K.; Tawney, J.; Hanahan, D.; Michael, I.P.; et al. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. 2017, 9, eaak6679. [CrossRef]

78. Huang, Y.; Yuan, J.; Righi, E.; Kamoun, W.S.; Ancukiewicz, M.; Nezivar, J.; Santosuosso, M.; Martin, J.D.; Martin, M.R.; Vianello, F.; et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. USA 2012, 109, 17561–17566. [CrossRef]

79. Shrimali, R.K.; Yu, Z.; Theoret, M.R.; Chinnasamy, D.; Restifo, N.P.; Rosenberg, S.A. Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer. Cancer Res. 2010, 70, 6171–6180. [CrossRef]

80. Nayak, L.; Molinaro, A.M.; Peters, K.B.; Clarke, J.L.; Jordan, J.T.; de Groot, J.F.; Nghiemphu, P.L.; Kaley, T.J.; Colman, H.; McCluskey, C.; et al. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin. Cancer Res. 2021, 27, 1048–1057. [CrossRef]

81. Lukas, R.V.; Rodon, J.; Becker, K.; Wong, E.T.; Shih, K.; Touat, M.; Fassó, M.; Osborne, S.; Molinero, L.; O’Hear, C.; et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J. Neuro Oncol. 2018, 140, 317–328. [CrossRef] [PubMed]

82. Wick, W.; Dettmer, S.; Berberich, A.; Kessler, T.; Karapanagiotou-Schenkel, I.; Wick, A.; Winkler, F.; Brors, B.; Debus, J.; et al. Nivolumab plus Bevacizumab in Patients with Recurrent Glioblastoma and Enhanced Immunotherapy: A Randomized Phase II Study. Neuro-Oncology 2019, 21, 4023. [CrossRef] [PubMed]

83.CORDNER, J.C.; De Cerio, A.L.-D.; Tejada, S.; et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Neuro-Oncology 2021, 23, 729–744. [CrossRef] [PubMed]

84. Woroniecka, K.; Chongsathidkiet, P.; Rhodin, K.; Kemeny, H.; Dechant, C.; Farber, S.H.; Elsamadicy, A.A.; Cui, X.; Koyama, S.; et al. Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma. Neuro-Oncology 2018, 20, 477–486. [PubMed] [CrossRef]

85. Sanders, C.M.; et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune activity and safety of atezolizumab in patients with recurrent glioblastoma. J. Neuro Oncol. 2020, 140, 4175–4186. [CrossRef]

86. Loghin, M.; et al. Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma. Neuro-Oncology 2020, 22, 234–243. [CrossRef] [PubMed]

87. Ott, M.; Prins, R.M.; Heimberger, A.B. The immune landscape of common CNS malignancies: Implications for immunotherapy. Nat. Rev. Clin. Oncol. 2021, 18, 729–744. [CrossRef] [PubMed]

88. Cloughesy, T.F.; Mochizuki, A.Y.; Orpilla, J.R.; Hugo, W.; Lee, A.H.; Davidson, T.B.; Wang, A.C.; Ellingson, B.M.; Bytelwowski, J.A.; Sanders, C.M.; et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 2019, 25, 477–486. [CrossRef]

89. Schalper, K.A.; Rodriguez-Ruiz, M.E.; Diez-Valle, R.; López-Janeiro, A.; Porciuncula, A.; Idoate, M.A.; Inogómez, S.; De Andrea, C.; De Cerio, A.L.-D.; Tejada, S.; et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat. Med. 2019, 25, 470–476. [CrossRef]

90. Topalian, S.L.; Taube, J.M.; Pardoll, D.M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 2020, 367, 6477. [CrossRef]

91. Amaria, R.N.; Reddy, S.; Tawbi, H.A.; Davies, M.A.; Ross, M.L; Glitza, I.C.; Cormier, J.N.; Lewis, C.; Huw, W.-J.; Hanna, E.; et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 2018, 24, 1649–1654. [CrossRef] [PubMed]

92. El Andaloussi, A.; Lesnai, M.S. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme1. Neuro-Oncology 2006, 8, 234–243. [CrossRef] [PubMed]
Cancers 2022, 14, 4023

93. Sharma, M.D.; Baban, B.; Chandler, P.; Hou, D.-Y.; Singh, N.; Yagita, H.; Azuma, M.; Blazar, B.R.; Mellor, A.L.; Munn, D.H. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Investig. 2007, 117, 2570–2582. [CrossRef] [PubMed]

94. Zhai, L.; Ladomersky, E.; Lauing, K.L.; Wu, M.; Genet, M.; Gritsina, G.; Győrfy, B.; Brastianos, P.K.; Binder, D.C.; Sosman, J.A.; et al. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin. Cancer Res. 2017, 23, 6650–6660. [CrossRef]

95. Wainwright, D.A.; Balyasnikova, I.V.; Chang, A.L.; Ahmed, A.U.; Moon, K.S.; Auffinger, B.; Tobias, A.L.; Han, Y.; Lesniak, M.S. IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival. IDO Regulates Treg Infiltration in Brain Tumors. Clin. Cancer Res. 2012, 18, 6110–6121. [CrossRef]

96. Ladomersky, E.; Zhai, L.; Lenzen, A.; Lauing, K.L.; Qian, J.; Schollens, D.M.; Gritsina, G.; Sun, X.; Liu, Y.; Yu, F.; et al. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin. Cancer Res. 2018, 24, 2559–2573. [CrossRef]

97. Kim, M.; Ladomersky, E.; Mozyk, A.; Kocherginsky, M.; O’Shea, K.; Reinstein, Z.Z.; Zhai, L.; Bell, A.; Lauing, K.L.; Bollu, L.; et al. Glioblastoma as an age-related neurological disorder in adults. Neuro-Oncol. Adv. 2021, 3. [CrossRef]

98. Lukas, R.; Sachdev, S.; Kumthekar, P.; Dixit, K.; Grimm, S.; Gondi, V.; Sharp, L.; Lezon, R.; James, D.; Lesniak, M.; et al. Ctim-12. a phase 1 trial of immunoradiotherapy with the ido enzyme inhibitor (bms-986205) and nivolumab in patients with newly diagnosed mgmt promoter unmethylated idhwt glioblastoma. Neuro-Oncol. 2021, 23 (Suppl. 6), vi51–vi52. [CrossRef]

99. Miska, J.; Rashidi, A.; Chang, A.L.; Muroski, M.E.; Han, Y.; Zhang, L.; Lesniak, M.S. Anti-GITR therapy promotes immunity against malignant glioma in a murine model. Cancer Immunol. Immunoother. 2016, 65, 1555–1567. [CrossRef]

100. Patel, M.A.; Kim, J.E.; Theodros, D.; Tam, A.; Velarde, E.; Kochel, C.M.; Francica, B.; Nirschl, T.R.; Ghämzemäd, A., Mathios, D.; et al. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J. Immunother. Cancer. 2016, 4, 28. [CrossRef]

101. Amoozgar, Z.; Kloepper, J.; Ren, J.; Tay, R.E.; Kazer, S.W.; Kiner, E.; Krishnan, S.; Posada, J.M.; Ghosh, M.; Mamessier, E.; et al. Targeting Tregs with GTR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat. Commun. 2021, 12, 1–16. [CrossRef] [PubMed]

102. Heimerberger, A.B.; Abou-Ghazaleh, M.; Reina-Ortiz, C.; Yang, D.S.; Sun, W.; Qiao, W.; Hiraoka, N.; Fuller, G.N. Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas. Clin. Cancer Res. 2008, 14, 5166–5172. [CrossRef] [PubMed]

103. Cohen, E.E.W.; Pishvaian, M.J.; Shepard, D.R.; Wang, D.; Weiss, J.; Johnson, M.L.; Chung, C.H.; Chen, Y.; Huang, B.; Davis, C.B.; et al. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J. Immunother. Cancer. 2019, 7, 342. [CrossRef] [PubMed]

104. Segal, N.H.; He, A.R.; Doi, T.; Levy, R.; Bhatia, S.; Pishvaian, M.J.; Cesari, R.; Chen, Y.; Davis, C.B.; Huang, B.; et al. Phase I Study of Single-Antigen Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. Clin. Cancer Res. 2018, 24, 1816–1823. [CrossRef]

105. Desjardins, A.; Chandramohan, V.; Landi, D.B.; Johnson, M.O.; Khasraw, M.; Peters, K.B.; Low, J.; Herndon, J.E.; Threatt, S.; Bullock, C.A.; et al. A phase 1 trial of DC27-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG). J. Clin. Oncol. 2022, 40, e14015. [CrossRef]

106. Brock, C.S.; Newlands, E.S.; Wedge, S.R.; Bower, M.; Evans, H.; Colquhoun, I.; Roddie, M.; Glaser, M.; Brampton, M.H.; Rustin, G.J. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998, 58, 4363–4367. [CrossRef]

107. Campian, J.L.; Piotrowski, A.F.; Ye, X.; Hakim, F.T.; Rose, J.; Yan, X.-Y.; Lu, Y.; Gress, R.; Grossman, S.A. Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide. J. Neuro-Oncology 2017, 135, 343–351. [CrossRef]

108. Mathios, D.; Kim, J.E.; Mangraviti, A.; Phallen, J.; Park, C.-K.; Jackson, C.M.; Garzon-Muvdi, T.; Kim, E.; Theodros, D.; Polanczyk, M.; et al. Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci. Transl. Med. 2016, 8, 370ra180. [CrossRef]

109. Karachi, A.; Yang, C.; Dastmalchi, F.; Sayour, E.J.; Huang, J.; Azari, H.; Long, Y.; Flores, C.; Mitchell, D.; Rahman, M. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro-Oncology 2019, 21, 730–741. [CrossRef]

110. Zhang, P.; Miska, J.; Lee-Chang, C.; Rashidi, A.; Panek, W.K.; An, S.; Zannikou, M.; Lopez-Rosas, A.; Han, Y.; Xiao, T.; et al. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. Proc. Natl. Acad. Sci. USA 2019, 116, 23741–23723. [CrossRef]

111. Patel, A.P.; Tiros, I.; Trombetta, J.J.; Shalek, A.K.; Gillespie, S.M.; Wakimoto, H.; Cahill, D.P.; Nahed, B.V.; Curry, W.T.; Martuza, R.L.; et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014, 344, 1396–1401. [CrossRef] [PubMed]

112. Sottriva, A.; Sperthi, I.; Piccirillo, S.G.M.; Toulousis, A.; Collins, VP.; Marioni, J.C.; Curtis, C.; Watts, C.; Tavare, S. Intradomain heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA 2013, 110, 4009–4014. [CrossRef] [PubMed]
113. Wei, W.; Shin, Y.S.; Xue, M.; Matsutani, T.; Masui, K.; Yang, H.; Ikogami, S.; Gu, Y.; Herrmann, K.; Johnson, D.; et al. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. *Cancer Cell* 2016, 29, 563–573. [CrossRef]

114. Parsa, A.T.; Waldron, J.S.; Panner, A.; Crane, C.A.; Parney, I.F.; Barry, J.J.; Cachola, K.E.; Murray, J.C.; Tihan, T.; Jensen, M.C.; et al. Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma. *Science* 2014, 343, 189–193. [CrossRef]

115. Kim, H.; Zheng, S.; Amini, S.S.; Virk, S.M.; Mikkelsen, T.; Brat, D.J.; Grimsby, J.; Sougnez, C.; Muller, F.; Hu, J.; et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. *Genome Res.* 2015, 25, 316–327. [CrossRef]

116. Wang, J.; Cazzato, E.; Ladewig, E.; Frattini, V.; Rosenbloom, D.I.S.; Zairis, S.; Abate, F.; Liu, Z.; Elliott, O.; Shin, Y.-J.; et al. Clonal evolution of glioblastoma under therapy. *Nat. Genet.* 2016, 48, 768–776. [CrossRef] [PubMed]

117. Carvalho, H.d.A.; Villar, R.C. Radiotherapy and immune response: The systemic effects of a local treatment. *Clinics* 2018, 73 (Suppl. 1), e557-563. [CrossRef]

118. Wu, Q.; Allouch, A.; Martins, I.; Brenner, C.; Modjtahedi, N.; Deutsch, E.; Perfettini, J.L. Modulating both tumor cell death and innate immunity is essential for improving radiation therapy effectiveness. *Front. Immunol.* 2017, 8, 613. [CrossRef]

119. Cao, M.; Cabrera, R.; Xu, Y.; Liu, C.; Nelson, D. Different radiosensitivity of CD4 T cells in glioblastoma. *Cancers* 2022, 119. [CrossRef]

120. Arrieta, V.A.; Iwamoto, F.; Lukas, R.V.; Sachdev, S.; Rabdan, R.; Sonabend, A.M. Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma? *J. Neurosurg.* 2019, 132, 1667–1672. [CrossRef]

121. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. *N. Engl. J. Med.* 2012, 366, 2443–2454. [CrossRef] [PubMed]

122. Wei, W.; Shin, Y.S.; Xue, M.; Matsutani, T.; Masui, K.; Yang, H.; Ikogami, S.; Gu, Y.; Herrmann, K.; Johnson, D.; et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. *Genome Res.* 2015, 25, 316–327. [CrossRef]

123. Hodges, T.R.; Ott, M.; Xiu, J.; Gatalica, Z.; Swensen, J.; Zhou, S.; Huse, J.T.; De Groot, J.; Li, S.; Overwijk, W.W.; et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: Implications for immune checkpoint immunotherapy. *Neuro-Oncology* 2017, 19, 1047–1057. [CrossRef] [PubMed]

124. Dhillon, A.S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer. *Oncogene* 2007, 26, 3279–3290. [CrossRef] [PubMed]
136. Arrieta, V.A.; Chen, A.X.; Kane, J.R.; Kang, S.J.; Kassab, C.; Dmello, C.; Zhao, J.; Burdett, K.B.; Upadhyayula, P.S.; Lee-Chang, C.; et al. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. *Nat. Cancer 2021*, 2, 1372–1386. [CrossRef] [PubMed]

137. Kane, J.R.; Zhao, J.; Tsujiuchi, T.; Laffleur, B.; Arrieta, V.A.; Mahajan, A.; Rao, G.; Mela, A.; Dmello, C.; Chen, L.; et al. CD8+ T-cell–Mediated Immunoeediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. *Clin. Cancer Res. 2020*, 26, 4390–4401. [CrossRef]

138. Osborn, A.J.; Elledge, S.J.; Zou, L. Checking on the fork: The DNA-replication stress-response pathway. *Trends Cell Biol. 2002*, 12, 509–516. [CrossRef]

139. McGrail, D.J.; Pilié, P.G.; Dai, H.; Lam, T.N.A.; Liang, Y.; Voorwerk, L.; Kok, M.; Zhang, X.H.-F.; Rosen, J.M.; Heimberger, A.B.; et al. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. *Sci. Transl. Med. 2021*, 13. [CrossRef]

140. Lim, M.; Xia, Y.; Bettegowda, C.; Weller, M. Current state of immunotherapy for glioblastoma. *Nat. Rev. Clin. Oncol. 2018*, 15, 422–442. [CrossRef]

141. Adair, R.A.; Roulstone, V.; Scott, K.J.; Morgan, R.; Nuovo, G.J.; Fuller, M.; Beirne, D.; West, E.J.; Jennings, V.A.; Rose, A.; et al. Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients. *Sci. Transl. Med. 2012*, 4, 138ra77. [CrossRef]

142. Stojdl, D.F.; Lichty, B.D.; Knowles, S.; Marius, R.; Atkins, H.; Sonenberg, N.; Bell, J.C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. *Nat. Med. 2000*, 6, 821–825. [CrossRef] [PubMed]

143. Shi, T.; Song, X.; Wang, Y.; Liu, F.; Wei, J. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. *Front. Pharmacol. 2020*, 11, 683. [CrossRef]

144. Zeng, J.; Li, X.; Sander, M.; Zhang, H.; Yan, G.; Lin, Y. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. *Front. Immunol. 2021*, 12. [CrossRef]

145. Shof, M.L.; Peters, K.B. Clinical Trials of Oncolytic Viruses in Glioblastoma. *Adv. Oncol. 2022*, 2, 139–158. [CrossRef]

146. Ager, C.R.; Reilley, M.J.; Nicholas, C.; Bartkowiak, T.; Jaiswal, A.R.; Curran, M.A. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. *Cancer Immunol. Res. 2017*, 5, 676–684. [CrossRef]

147. Sivick, K.E.; Desbien, A.L.; Glickman, L.H.; Reiner, G.L.; Corrales, L.; Surh, N.H.; Bell, J.C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. *Nat. Med. 2000*, 6, 821–825. [CrossRef] [PubMed]

148. Shi, T.; Song, X.; Wang, Y.; Liu, F.; Wei, J. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. *Front. Pharmacol. 2020*, 11, 683. [CrossRef]

149. Zeng, J.; Li, X.; Sander, M.; Zhang, H.; Yan, G.; Lin, Y. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. *Front. Immunol. 2021*, 12. [CrossRef]

150. Lim, M.; Xia, Y.; Bettegowda, C.; Weller, M. Current state of immunotherapy for glioblastoma. *Nat. Rev. Clin. Oncol. 2018*, 15, 422–442. [CrossRef]

151. Piperi, C.; Papavassiliou, K.A.; Papavassiliou, A.G. Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment. *Cells 2019*, 8, 1398. [CrossRef] [PubMed]

152. Ferguson, S.D.; Srinivasan, V.M.; Heimberger, A.B. The role of STAT3 in tumor-mediated immune suppression. *J. Neuro-Oncol. 2015*, 123, 385–394. [CrossRef] [PubMed]

153. Ouedraogo, Z.G.; Biau, J.; Kemeny, J.-L.; Morel, L.; Verrelle, P.; Chautard, E. Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. *Mol. Neurobiol. 2017*, 54, 5780–5797. [CrossRef] [PubMed]

154. Hussain, S.F.; Kong, D.-S.; Lee, H.W.; Nam, D.-H. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. *Cell. Mol. Endocrinol. 2017*, 451, 53–65. [CrossRef] [PubMed]

155. Chang, N.; Ahn, S.H.; Kong, D.-S.; Lee, H.W.; Nam, D.-H. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. *Cell. Mol. Endocrinol. 2017*, 451, 53–65. [CrossRef] [PubMed]

156. Hussain, S.F.; Kong, D.-S.; Lee, H.W.; Nam, D.-H. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. *Cell. Mol. Endocrinol. 2017*, 451, 53–65. [CrossRef] [PubMed]

157. de Groot, J.; Ott, M.; Wei, J.; Kassab, C.; Fang, D.; Najem, H.; O’Brien, B.; Weathers, S.-P.; Matsouka, C.K.; Majd, N.K.; et al. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. *CNS Oncol. 2020*, 11. [CrossRef]

158. Ott, M.; Kassab, C.; Marisetty, A.; Hashimoto, Y.; Wei, J.; Zamler, D.B.; Leu, J.-S.; Tomaszowski, K.-H.; Sabbagh, A.; Fang, D.; et al. Radiation with STAT3 Blockade Triggers Dendritic Cell–T cell Interactions in the Glia Microenvironment and Therapeutic Efficacy. *Clin. Cancer Res. 2020*, 26, 4983–4994. [CrossRef] [PubMed]

159. Sonabend, A.M.; Veluc, S.; Ulasow, I.V.; Han, Y.; Tyler, B.; Brem, H.; Matar, M.M.; Fewell, J.G.; Anwer, K.; Lesnaki, M.S. A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. *Anti-Cancer Drugs 2008*, 19, 133–142. [CrossRef]

160. Chiocca, E.A.; Yu, J.S.; Lukas, R.V.; Solomon, I.H.; Ligon, K.L.; Nakashima, H.; Triggs, D.A.; Reardon, D.A.; Wen, P.; Stopa, B.M.; et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. *Sci. Transl. Med. 2019*, 11. [CrossRef]
160. Chiocca, E.A.; Gelb, A.B.; Chen, C.C.; Rao, G.; Reardon, D.; Wen, P.Y.; Bi, W.L.; Peruzzi, P.; Amidei, C.; Triggs, D.; et al. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. *Neuro-Oncology* 2021, 24, 951–963. [CrossRef]

161. Lukas, R.; Oberheim-Bush, N.A.; Cavaliere, R.; Landolfi, J.; Yu, J.S.; Chen, C.; Cordova, C.; Amidei, C.; Buck, J.Y.; Hadar, N.; et al. CTIM-20. Final results of controlled IL-12 monotherapy and in combination with pd-1 inhibitor in adult subjects with recurrent glioblastoma. *Neuro-Oncology* 2021, 23, vi54. [CrossRef]

162. Lasek, W.; Zagóźdzon, R.; Jakobisiak, M. Interleukin 12: Still a promising candidate for tumor immunotherapy? *Cancer Immunol. Immunother.* 2014, 63, 419–435. [CrossRef]

163. Lotze, M.T. Interleukin 12: Cellular and molecular immunology of an important regulatory cytokine. *Introd. Ann. N. Y. Acad. Sci.* 1996, 795, xiii–xix. [CrossRef]

164. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. *Nat. Rev. Immunol.* 2003, 3, 133–146. [CrossRef]

165. Curtsinger, M.J.; Johnson, C.M.; Mescher, M.F. CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. *J. Immunol.* 2003, 171, 5165–5171.

166. Micallef, M.J.; Ohtsuki, T.; Kohno, K.; Tanabe, F.; Ushio, S.; Namba, M.; Tanimoto, T.; Torigoe, K.; Fujii, M.; Ikeda, M.; et al. Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: Synergism with interleukin-12 for interferon-γ production. *Eur. J. Immunol.* 1996, 26, 1647–1651. [CrossRef] [PubMed]

167. Reardon, D.A.; Brem, S.; Desai, A.S.; Bagley, S.J.; Kurz, S.C.; De La Fuente, M.I.; Nagpal, S.; Welch, M.R.; Hormigo, A.; Carroll, N.; et al. INO-5401 and INO-9012 delivered intramuscularly (IM) with electropropion (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. *J. Clin. Oncol.* 2020, 38, 2514. [CrossRef]

168. Van Vulpen, M.; Kal, H.B.; Taphoorn, M.J.; El Sharouni, S.Y. Changes in blood-brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy? (Review). *Oncol. Rep.* 2002, 9, 683–688. [CrossRef] [PubMed]

169. Qin, D.; Ma, J.; Xiao, J.; Tang, Z. Effect of Brain Irradiation on Blood-CSF Barrier Permeability of Chemotherapeutic Agents. *Am. J. Clin. Oncol.* 1997, 20, 263–265. [CrossRef] [PubMed]

170. Carpentier, A.; Canney, M.; Vignot, A.; Reina, V.; Beccaria, K.; Horodyckid, C.; Karachi, C.; Leclercq, D.; Lafon, C.; Chapelon, J.-Y.; et al. Clinical trial of brain-brain barrier disruption by pulsed ultrasound. *Sci. Transl. Med.* 2016, 8, 343re2. [CrossRef]

171. Mainprize, T.; Lipsman, N.; Huang, Y.; Meng, Y.; Bethune, A.; Ironside, S.; Heyn, C.; Alkins, R.; Trudeau, M.; Sahgal, A.; et al. Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study. *Sci. Rep.* 2019, 9, 321. [CrossRef]

172. Dréan, A.; Lemaire, N.; Bouchoux, G.; Goldwirt, L.; Canney, M.; Goli, L.; Bouzidi, A.; Schmitt, C.; Guehennec-J, V.; Verreault, M.; et al. Temporary blood–brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma. *J. Neuro-Oncol.* 2019, 144, 33–41. [CrossRef] [PubMed]

173. Idbaih, A.; Canney, M.; Belin, L.; Desseaux, C.; Vignot, A.; Bouchoux, G.; Asquier, N.; Law-Ye, B.; Leclercq, D.; Bissery, A.; et al. Safety and feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. *Clin. Cancer Res.* 2019, 25, 3793–3801. [CrossRef] [PubMed]

174. Sonabend, A.M.; Gould, A.; Luo, Y.; Hou, Y.; Chen, L.; Kobayashi, M.A.; Castro, B.A.; Zhang, D.Y.; Korobova, F.V.; Amidei, C.; et al. Repeated opening of the blood-brain barrier with the skull-implantable Sonocloud-9 (SC9) device: Phase 1 trial of nab-paclitaxel and SC9 in recurrent glioblastoma. *J. Clin. Oncol.* 2020, 40, 2016. [CrossRef]

175. Zhang, D.Y.; Dmello, C.; Chen, L.; Arrieta, V.A.; Gonzalez-Buendia, E.; Kane, J.R.; Magnusson, L.P.; Baran, A.; James, C.D.; Horbinski, C.; et al. Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor FormulationsUS-Delivered ABX Extends Survival in GBM PDX Mouse Model. *Clin. Cancer Res.* 2020, 26, 477–486. [CrossRef]

176. Lau, T.S.; Chan, L.K.Y.; Man, G.C.W.; Wong, C.H.; Lee, J.H.S.; Cheung, T.H.; McNeish, I.A.; Kwong, J. Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4/IKK2/SNARE-dependent exocytosis. *Cancer Immunol. Res.* 2020, 8, 1099–1111. [CrossRef] [PubMed]

177. Decraene, B.; Yang, Y.; De Smet, F.; Garg, A.D.; Agostinis, P.; De Vleeschouwer, S. Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma. *Genes Immun.* 2022, 23, 1–11. [CrossRef]

178. Sabbagh, A.; Beccaria, K.; Ling, X.; Marisette, A.; Ott, M.; Caruso, H.; Barton, E.; Kong, L-Y.; Fang, D.; Latha, K.; et al. Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. *Clin. Cancer Res.* 2021, 27, 4325–4337. [CrossRef] [PubMed]

179. Klemm, F.; Maas, R.R.; Bowman, R.L.; Kornet, M.; Soukup, K.; Nassiri, S.; Brouland, J.-P.; Iacobuzio-Donahue, C.A.; Brennan, C.; Tabar, V.; et al. Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. *Cell 2020, 181, 1643–1660. [CrossRef]

180. Thorsson, V.; Gibbs, D.L.; Brown, S.D.; Wolf, D.; Bortone, D.S.; Ou Yang, T.-H.; Porta-Pardo, E.; Gao, G.F.; Plaisier, C.L.; Eddy, J.A.; et al. The Immune Landscape of Cancer. *Immunity* 2018, 48, 812–830.e14. [CrossRef]

181. Alban, T.J.; Alvarado, A.G.; Sorensen, M.D.; Bayik, D.; Voltovetz, J.; Serbinowski, E.; Mulkerns-Hubert, E.E.; Sinyuk, M.; Hale, J.S.; Onzi, G.R.; et al. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. *JCI Insight* 2018, 3, e122264. [CrossRef] [PubMed]
182. Raychaudhuri, B.; Rayman, P.; Ireland, J.; Ko, J.; Rini, B.; Borden, E.C.; Garcia, J.; Vogelbaum, M.A.; Finke, J. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. *Neuro-Oncology* 2011, 13, 591–599. [CrossRef] [PubMed]

183. Chang, A.L.; Miska, J.; Wainwright, D.A.; Dey, M.; Rivetta, C.V.; Yu, D.; Kanojia, D.; Pituch, K.C.; Qiao, J.; Pytel, P.; et al. CCL2 Produced by the glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor CellsCCL2 in Treg and MDSC Trafficking to Glioma. *Cancer Res.* 2016, 76, 5671–5682. [CrossRef] [PubMed]

184. Bayik, D.; Zhou, Y.; Park, C.; Hong, C.; Vail, D.; Silver, D.J.; Lauko, A.; Roversi, G.; Watson, D.C.; Lo, A.; et al. Myeloid-Derived Suppressor Cells Drive Glioblastoma Growth in a Sex-Specific MannerMDSC Subset Sexual Dimorphism Informs GBM Immunotherapy. *Cancer Discov.* 2020, 10, 1210–1225. [CrossRef] [PubMed]

185. Flores-Toro, J.A.; Luo, D.; Gopinath, A.; Sarkisian, M.R.; Campbell, J.J.; Charo, I.F.; Singh, R.; Schall, T.J.; Datta, M.; Jain, R.K.; et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. *Proc. Natl. Acad. Sci. USA* 2020, 117, 1129–1138. [CrossRef] [PubMed]

186. Miska, J.; Rashidi, A.; Lee-Chang, C.; Gao, P.; Lopez-Rosas, A.; Zhang, P.; Burga, R.; Castro, B.; Xiao, T.; Han, Y.; et al. Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma. *Sci. Adv.* 2021, 7, eabc8929.

187. Peereboom, D.M.; Alban, T.J.; Grabowski, M.M.; Alvarado, A.G.; Otvos, B.; Bayik, D.; Roversi, G.; McGraw, M.; Huang, P.; Mohammadi, A.M.; et al. Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. *JCI Insight* 2019, 4. [CrossRef]

188. Pyonteck, S.M.; Akkari, L.; Schuhmacher, A.J.; Bowman, R.L.; Sevenich, L.; Quail, D.F.; Olson, O.C.; Quick, M.L.; Huse, J.T.; Tejeiro, V.; et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. *Nat. Med.* 2013, 19, 1264–1272. [CrossRef]

189. Akkari, L.; Bowman, R.L.; Tessier, J.; Klemm, F.; Handgraaf, S.M.; de Groot, M.; Quail, D.F.; Tillard, L.; Gadiot, J.; Huse, J.T.; et al. Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. *Sci. Transl. Med.* 2020, 12. [CrossRef]

190. Lin, C.-C.; Gil-Martin, M.; Bauer, T.M.; Naing, A.; Lim, D.W.-T.; Sarantopoulos, J.; Geva, R.; Ando, Y.; Fan, L.; Choudhury, S.; et al. Abstract CT171: Phase I study of BLZ945 alone and with spartalizumab (PDR001) in patients (pts) with advanced solid tumors. *Cancer Res. 2020*, 80, CT171. [CrossRef]

191. Butowski, N.; Colman, H.; De Groot, J.F.; Omuro, A.M.; bayik, D.; Roversi, G.; McGraw, M.; Huang, P.; Perry, A.; et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study. *Neuro-Oncology* 2016, 18, 557–564. [CrossRef] [PubMed]

192. Sarkar, S.; Yang, R.; Mirzaei, R.; Ravji, K.; Poon, C.; Mishra, M.K.; Zemp, F.J.; Bose, P.; Kelly, J.; Dunn, J.F.; et al. Control of brain tumor growth by reactivating myeloid cells with niacin. *Sci. Transl. Med.* 2020, 12. [CrossRef] [PubMed]

193. Daher, M.; Rezvani, K. Next generation natural killer cells for cancer immunotherapy: The promise of genetic engineering. *Curr. Opin. Immunol.* 2018, 51, 146–153. [CrossRef]

194. Shaim, H.; Shanley, M.; Basar, R.; Daher, M.; Gumin, J.; Zamler, D.B.; Uprety, N.; Wang, F.; Gabrusiewicz, K.; et al. Next generation natural killer cells for cancer immunotherapy: The promise of genetic engineering. *Curr. Opin. Immunol.* 2018, 51, 146–153. [CrossRef]

195. Shahi, S.; Shanley, M.; Basar, R.; Daher, M.; Gumin, J.; Zamler, D.B.; Uprety, N.; Wang, F.; Gabrusiewicz, K.; et al. Targeting the αβ integrin/TFG-β axis improves natural killer cell function against glioblastoma stem cells. *J. Clin. Investig.* 2021, 131. [CrossRef]

196. Kabelitz, D.; Serrano, R.; Kouakounou, L.; Peters, C.; Kalyan, S. Cancer immunotherapy with γδ T cells: Many paths ahead of us. *Cell. Mol. Immunol.* 2020, 17, 925–939. [CrossRef]

197. Groh, V.; Rhinehart, R.; Secrist, H.; Bauer, S.; Grabstein, K.H.; Spies, T. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. *Proc. Natl. Acad. Sci. USA* 1999, 96, 6879–6884. [CrossRef]

198. Fujimori, Y.; Suzuki, Y.; Katakura, R.; Miyagi, T.; Yamaguchi, T.; Yoshimoto, T.; Ebina, T. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients. *Clin. Cancer Res.* 1997, 3, 633–643. [PubMed]

199. Yamaguchi, T.; Fujimori, Y.; Suzuki, Y.; Katakura, R.; Ebina, T. A simple method for the propagation and purification of γδ T cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2. *J. Immunol. Methods* 1997, 205, 19–28. [CrossRef]

200. Nabors, L.B.; Lamb, L.S.; Beelen, M.J.; Pillay, T.; ter Haak, M.; Youngblood, S.; Vaickus, L.; Lobbous, M. Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ T cells and temozolomide chemotherapy in newly diagnosed glioblastoma. *J. Clin. Oncol.* 2021, 39, 2057. [CrossRef]

201. Nabors, L.B.; Lobbous, M.; Lamb, L.S.; Rochlin, K.; Pillay, T.; Youngblood, S.; Haak, M.; Goswami, T. “Phase I study of drug-resistant immunotherapy (DRI) with gene-modified autologous γδ T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide chemotherapy (TMZ).” *J. Clin. Oncol.* 2022, 40, 2044. [CrossRef]

202. Cabrita, R.; Lauss, M.; Sanna, A.; Donate, M.; Larsen, M.S.; Mitra, S.; Johansson, I.; Fung, B.; Harbst, K.; Vallon-Christersson, J.; et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. *Nature 2020*, 577, 561–565. [CrossRef]

203. Garg, K.; Maurer, M.; Griss, J.; Brüggen, M.-C.; Wolf, I.H.; Wagner, C.; Willi, N.; Mertz, K.D.; Wagner, S.N. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. *Hum. Pathol.* 2016, 54, 157–164. [CrossRef] [PubMed]

204. Mahmoud, S.; Lee, A.H.S.; Paiash, E.C.; Macmillan, R.D.; Ellis, I.; Green, A.R. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. *Breast Cancer Res. Treat.* 2011, 132, 545–553. [CrossRef] [PubMed]
204. Edin, S.; Kaprio, T.; Hagström, J.; Larsson, P.; Mustonen, H.K.; Böckelman, C.; Strigård, K.; Gunnarsson, U.; Haglund, C.; Palmqvist, R. The Prognostic Importance of CD20+ B lymphocytes in Colorectal Cancer and the Relation to Other Immune Cell subsets. Sci. Rep. 2019, 9, 19997–19999. [CrossRef] [PubMed]

205. Griss, J.; Bauer, W.; Wagner, C.; Simon, M.; Chen, M.; Grabmeier-Pfistershammer, K.; Maurer-Granofszky, M.; Roka, F.; Penz, T.; Bock, C.; et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 2019, 10, 4186. [CrossRef]

206. van Herpen, C.M.; van der Voort, R.; van der Laak, J.A.; Klasen, I.S.; de Graaf, A.O.; van Kempen, L.C.; de Vries, I.J.; Boer, T.D.; Dolstra, H.; Torensm, R.; et al. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int. J. Cancer 2008, 123, 2354–2361. [CrossRef]

207. Santoiemma, P.P.; Reyes, C.; Wang, L.-P.; McLane, M.W.; Feldman, M.D.; Tanyi, J.L.; Powell, D.J. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol. Oncol. 2016, 143, 120–127. [CrossRef]

208. Goepert, B.; Frauenschuh, L.; Zucknick, M.; Andruslis, M.; Klauschen, F.; Joehrens, K.; Warth, A.; Renner, M.; Mehrabi, A.; et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br. J. Cancer 2013, 109, 2665–2674. [CrossRef]

209. Lee-Chang, C.; Bodogai, M.; Moritoh, K.; Olkhanud, P.B.; Chan, A.C.; Croft, M.; Mattison, J.A.; Holst, P.J.; Gress, R.E.; Ferrucci, L.; et al. Accumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity. Blood 2014, 124, 1450–1459. [CrossRef]

210. Lee-Chang, C.; Miska, J.; Hou, D.; Rashidi, A.; Zhang, P.; Burga, R.A.; Jusué-Torres, I.; Xiao, T.; Arrieta, V.A.; Zhang, D.Y.; et al. Activation of 4-1BBL+ B cells with CD40 agonism and IFNy elicits potent immunity against glioblastoma. J. Exp. Med. 2021, 218, e20200913. [CrossRef]